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Breast cancer is currently the most common cancer among women globally. Triple-
negative breast cancer (TNBC) is an aggressive and often drug-resistant sub-type of 
breast cancer that is correlated with poor patient outcomes. As a result, adjuvant 
therapies that may improve drug sensitivity are currently being sought. Due to the 
unique metabolic hallmarks of cancer, metabolic adjuvant therapies have become an 
area of increasing interest. We therefore set out to investigate the effect of short-term 
starvation (STS) on the growth, viability, and metabolism of TNBC cells and a benign 
breast epithelial cell line. We also investigated the effect of STS on chemotherapy-
induced cytotoxicity in these cells to determine whether STS may enhance the effect 
of doxorubicin in TNBC.  
 
Methods: 
Three cell lines were utilised for this study: a benign breast epithelial cell line (MCF-
12A), and two triple-negative breast cancer cell lines (BT-549 and MDA-MB-231). 
Western blotting was employed to determine the effect of starvation over time on 
growth and proliferation signalling pathways (PI3K/Akt) and markers of autophagy 
(Atg5, p62 and LC3-II). Immunocytochemistry was utilised to quantify autophagic 
puncta. Cell cycle progression and viability were assessed using flow cytometry and 
a WST1 assay, respectively. The effect of STS on chemosensitivity was then 
established by incubating cells in standard or starvation-mimicking media for 24 hours, 
whereafter they received doxorubicin at a concentration of 2.5 µM. Chemosensitivity 








Results and Discussion: 
In response to STS, the MCF-12A cells downregulated pro-growth signalling 
pathways, while the MDA-MB-231 cells showed significant upregulation. A 24-hour 
starvation period had no significant effects on these pathways or on autophagic flux in 
the BT-549 cells. Both the MCF-12A and MDA-MB-231 cell lines significantly 
upregulated autophagic flux in response to STS, with the latter achieving the most 
significant effect at 24-hours. This may have offered protection to these cells, as a 
period of starvation prior to drug administration reduced doxorubicin-induced G2/M 
arrest. Additionally, STS had no other significant effects on chemosensitivity in these 
cells. In the BT-549 cells, however, starvation was able to significantly increase the 
percentage of dead cells in the group that received STS prior to doxorubicin treatment. 
As autophagy was not significantly increased in this cell line during starvation, this 
suggests that autophagy may indeed play a role in drug resistance. 
 
Conclusion: 
In summary, the cell lines which displayed an upregulation of autophagy at 24 hours 
of starvation were not sensitised to doxorubicin in terms of cell death, and also 
experienced amelioration of doxorubicin-induced G2/M arrest. This supports the notion 
that autophagic upregulation may protect cancer cells from doxorubicin-induced 
cytotoxicity and contribute to drug resistance. However, to gain a more thorough 
understanding of this phenomenon, future studies investigating the mechanisms by 







Borskanker is die mees algemene kanker in vroue wêreldwyd. Trippel negatiewe 
borskanker (TNBK) is ‘n aggressiewe en menigmaal ‘n middel-weerstandige subtipe 
borskanker wat met ‘n swak prognose geassosieer word. As gevolg hiervan, word 
adjuvante terapeutiese opsies ondersoek om middel sensitiwiteit te verbeter. 
Metaboliese adjuvante terapeutitese opsies word toenemend ondersoek as gevolg 
van die unieke metaboliese kenmerke van kanker. Die doel van hierdie studie was om 
die effek van kort termyn uithongering (KTU) op selgroei, sel lewensvatbaarheid en 
metabolisme in TNBK selle en benigne bors epiteelselle te ondersoek. Die effek van 
KTU op chemosensitiwiteit in hierdie selle is ook ondersoek om te bepaal of dit as ‘n 
moontlike behandelingsopsie kan dien. 
 
Metodes: 
Drie sellyne is in hierdie studie gebruik: ‘n benigne borsepiteel sellyn (MCF-12A), en 
twee TNBK sellyne (BT-549 en MDA-MB-231). Westelike kladtegniek is gebruik om 
die effek van uithongering oor tyd op selgroei seinoordragpaaie (PI3K/Akt) en merkers 
van autofagie te bepaal (Atg5, p62 en LC3-II). Immunositochemie is gebruik om 
autofagie punktae te kwantifiseer. Selsiklus progressie en sel lewensvatbaarheid is 
deur middel van vloeisitometrie en ‘n WST-1 toets onderskeidelik bepaal. Die effek 
van KTU op chemosensitiwiteit is bepaal deur selle in standaard- en uithongering 
nabootsende media vir 24 uur te inkubeer waarna dit doxorubicin teen ‘n konsentrasie 
van 2.5 M ontvang het. Chemosensitiwiteit is daarna vasgestel deur middel van die 








Resultate en Bespreking: 
Die MCF-12A selle het groei seinoordragpaaie afgereguleer in reaksie op KTU, terwyl 
die MDA-MB-231 selle weer ‘n insiggewende opregulering van hierdie paaie getoon 
het. ‘n Vier-en-twintig uur uithongeringsperiode het geen insiggewende effek of hierdie 
paaie of autofagie vloei in die BT-549 selle gehad nie. Beide die MCF-12A en die 
MDA-MB-231 sellyne het autofagie vloei insiggewend opgereguleer in reaksie op 
KTU, met die MDA-MB-231 selle wat die mees insiggewende effek na 24 uur getoon 
het. Dit kon beskerming aan hierdie selle gebied het, aangesien die 
uithongeringstydperk voor die toediening van doxorubicin, die doxorubicin-
geinduseerde G2/M inperking verminder het. KTU het geen verdere effek ten opsigte 
van chemosensitiwiteit in hierdie sellyne gehad nie. In die BT-549 selle, het 
uithongering die persentasie dooie selle insiggewend verhoog in die groep wat KTU 
ondergaan het voor doxorubicin behandeling. Autofagie vloei was nie insiggewend 
verhoog tydens uithangering in hierdie groep nie wat moontlik kan beteken dat 
autofagie inderdaad ‘n rol in middelweerstandigheid in hierdie sellyne speel. 
 
Gevolgtrekking: 
Ter opsomming, die sellyne wat ‘n opregulering in autofagie vloei getoon het na 24 
uur uithongering, is nie gesentitiseer vir doxorubicin in terme van seldood nie en het 
verder ook vermindering in doxorubicin-geinduseerde G2/M inperking getoon. Dit 
ondersteun die begrip dat autofagie opregulering kankerselle teen doxorubicin-
geinduseerde sitotoksisiteit beskerm en middelweerstandigheid kan bewerkstellig. 
Om ‘n meer breedvoerige verstaan van hierdie fenomeen te verkry, word verdere 
studies aanbeveel wat die meganismes ondersoek waardeur autofagie beskerming 
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Chapter 1: Literature Review 
 
1.1 Cancer in context 
 
1.1.1 Definition, global and local incidence, and risk factors 
Cancer may be defined as the uncontrolled division of cells, leading to abnormal growth and 
differentiation, the invasion of surrounding tissues, and spread to distal parts of the body 
(WHO, 2018). 
In 2018, a diagnosis of cancer was given to approximately 18 million people worldwide, 
with a further 9.6 million deaths having been caused by the disease (WHO, 2018). 
Globally, one in six people are predicted to develop cancer throughout their lifetime, 
with alarming increases in incidence over the past several decades (WHO, 2018).  
With approximately 70% of cancer-related deaths occurring in low- to middle-income 
countries (WHO, 2018), South Africa is no exception to these high prevalence rates. 
In the South African context, one in seven men and one in eight women will be 
diagnosed with cancer during their lifetime (CANSA, 2019). The most common types 
of cancer, by sex, are as follows: 
Males Females 
Prostate cancer (19,18%) Breast cancer (21,78%) 
Colorectal cancer (5,28%) Cervical cancer (15,17%) 
Lung cancer (4,87%) Cancer of unknown primary origin 
(4,47%) 
Cancer of unknown primary origin 
(4,73%) 
Colorectal cancer (4,29%) 
Kaposi sarcoma (2,66%) Cancer of the uterus (3,32%) 
Table 1.1: The most commonly diagnosed types of cancer in the South African population, by gender, 





Figure 1.1: Increases in incidence of the top five cancers affecting women in South Africa (CANSA, 
2014). 
With breast cancer being the most commonly diagnosed cancer in South Africa 
(CANSA, 2014), and the fifth leading cause of cancer-related deaths worldwide (WHO, 
2018), increasingly more research is being conducted in order to better understand 
the causes, risk factors, mechanisms and potential treatments for breast cancer. 
Currently, the disease is understood to be the result of complex interactions between 
a wide variety of known and unknown factors (Blackadar, 2016). The discovery of the 
BRCA1 and BRCA2 genes led to the understanding of a strong genetic component in 
certain breast cancers (Dumalaon-Canaria, et al., 2014). This was further elucidated 
by the identification of the TP53 gene (Elmore, 2007). Besides heredity, diet, lifestyle 
and environmental factors also play an additional role in the development of breast 
cancer (Gonzalez & Riboli, 2010; CANSA, 2019). Protective factors include physical 
activity, maintaining a healthy body weight, and breast-feeding, while risk factors 




use of tobacco, and alcohol consumption (Gonzalez & Riboli, 2010; CANSA, 2019). 
Prolonged exposure to endogenous oestrogens, such as early menarche, or the late 
onset of menopause, represent non-modifiable risk factors, while the use of 
exogenous oestrogens (in the form of combined oral contraceptives and hormone 
replacement therapy) are considered modifiable risk factors with the same underlying 
mechanism (Kulkoyluoglu-Cotul, et al., 2019). 
 
1.1.2 Types of breast cancer and current treatment regimes 
Breast cancer, in pathology, is quite diverse. Breast cancer may originate at different 
sites within the breast and is usually named accordingly. The most common types of 
breast cancer include those in the milk-producing lobules (lobular carcinoma in situ 
and invasive lobular carcinoma) as well as those in the milk-storing ducts (ductal 
carcinoma in situ and invasive ductal carcinoma) (Kulkoyluoglu-Cotul, et al., 2019). 
Rare types of breast cancer include inflammatory breast cancer, Phyllode’s tumours 
of the breast, Paget’s disease of the nipple, and male breast cancer (Waks & Winer, 
2019). Beyond classification according to the tumour site, breast cancer may be 
subtyped according to its molecular profile, that is, whether it expresses receptors on 
the cell surface for oestrogen, progesterone, or human epidermal growth factor 
receptor 2 (HER2) (Kulkoyluoglu-Cotul, et al., 2019). Luminal A, luminal B, normal-like 
and HER2-enriched breast cancers all express one or more of the aforementioned 
receptors, and are thus candidates for targeted therapies (Foulkes, et al., 2010). 
However, triple-negative breast cancer (TNBC) represents a class of cancers which 
does not express any of the three receptors listed. TNBC represents 10-20% of all 
breast cancer cases and is often more difficult to treat as targeted therapies are not 
indicated (Foulkes, et al., 2010). TNBC is also more aggressive, shows resistance to 
treatment, and has the poorest prognosis of all the molecular subtypes of breast 
cancer (Foulkes, et al., 2010). 
In non-TNBC, targeted and hormonal therapies represent an efficacious method to 
attack cancer cells specifically, as they express the receptors to which the drugs can 
bind. However, when targeted treatments are not indicated, as in the case of TNBC, 
the three main therapeutic avenues include surgery, radiation therapy, and 




cancerous tissue, as well as some adjacent tissue, to prevent recurrence (Waks & 
Winer, 2019). Surgical procedures may involve removing the affected region 
(lumpectomy), or the entire breast (mastectomy) in more severe cases (Waks & Winer, 
2019).  
Radiation treatment involves the delivery of ionising beams to the tumour and 
surrounding tissues in order to kill malignant cells. Acute side effects include fatigue, 
nausea, vomiting and mucositis (Mahan, et al., 2012). Additionally, there has been 
significant controversy over whether radiation therapy may increase the relative risk 
of developing cancer in the future, due to the mutagenic effect of ionising radiation 
(Waks & Winer, 2019). 
Chemotherapy, on the other hand, involves the use of cytotoxic drugs administered 
orally or intravenously. One of the most common chemotherapeutic agents indicated 
for the treatment of breast cancer includes doxorubicin, an anthracycline (Waks & 
Winer, 2019). Doxorubicin has two predominant mechanisms of actions whereby it 
eliminates cancer cells. The first involves the production of free radicals, which 
damage multiple cellular components: lipids in organelle and cell membranes, 
intracellular proteins, and DNA (McClendon & Osheroff, 2007). The second is through 
more targeted damage that is specific to DNA. Doxorubicin renders DNA dysfunctional 
by intercalating into the strands and prevents both DNA repair and replication by 
inhibiting the enzyme topoisomerase II (McClendon & Osheroff, 2007). When DNA 
unwinds for transcription, supercoils form in the strands that could lead to tangles, or 
superhelical twists. In order to relieve this torsional stress, topoisomerase II creates a 
transient double-stranded break in the DNA, and then passages the double-stranded 
DNA once the supercoil is relaxed (McClendon & Osheroff, 2007). Inhibition of this 
process prevents DNA replication and may lead to mitotic cell death. Ultimately, the 
drug targets rapidly dividing cells and promotes apoptosis with the goal of eliminating 
the cancer cells (Waks & Winer, 2019). Chemotherapy, however, has several 
disadvantages, as there may be acute or chronic side effects of varying severity. 
Typical side effects include nausea, vomiting, diarrhoea, mucositis, hair loss, fatigue 
and headaches (Mahan, et al., 2012). More severe side effects include a drastic loss 
of lean body mass which can increase morbidity and result in poorer clinical outcomes; 
neutropenia which can impair immune function; thrombocytopenia, which can facilitate 




side effects of chemotherapy include osteoporosis, cardiac hypertrophy, cachexia and 
cardiac failure (Safdie, et al., 2009).  
1.1.3 Rationale and potential for adjuvant therapies 
In summary, therapies are generally only indicated if the oncologist or clinician 
considers the risks as outweighed by the potential benefit, as all modes of treatment 
present with both advantages and disadvantages. For this reason, adjuvant therapies 
have become an increasingly popular area of research over the past two decades 
(Chew, 2001). Adjuvant therapies are therapies which are used prior to or alongside 
surgery or other cancer treatments in order to: a) reduce the acute side effects of the 
main treatment, b) to protect the patient from severe and chronic complications, or c) 
to heighten the sensitivity of malignant cells to treatment, thereby increasing treatment 
efficacy (Chew, 2001). Adjuvant therapy has been described as a “helping hand”, not 
to replace existing therapies, but rather to render them more effective (Chew, 2001).  
As of late, there has been a surge in the branch of research concerned with dietary 
adjuvant therapies. Considering the role played by obesity, dietary factors and 
metabolic alterations in the pathogenesis and propagation of cancer (Berger, 2014; 
Gonzalez & Riboli, 2010), metabolic interventions may thus hold the potential to serve 
as an adjuvant therapy alongside the treatment of cancer. Additionally, as the body of 
literature surrounding cancer metabolism has expanded, so too has the potential for 
targeting these metabolic vulnerabilities of cancer cells. However, in order to fully 
appreciate the potential for a dietary adjuvant therapy, the metabolism of normal tissue 
must be explored for the purpose of highlighting the distinguishing features of cancer 
metabolism. 
 
1.2  Metabolism and molecular pathways during the fed state 
 
1.2.1 The digestion and metabolic fate of lipids 
Typically, the majority of systemic daily energy requirements are met by exogenous 
fuels. A typical meal contains different forms of carbohydrates, protein and lipids, all 




Lipids are physically and chemically digested to yield monoacylglycerides and free 
fatty acids. These molecules are absorbed in the intestine in the form of micelles, and 
transported in chylomicrons through circulation to the liver, skeletal muscle and 
adipose tissue for either catabolism or storage (Sherwood, 2010). While lipids may be 
used for functional roles, such as to be incorporated into the lipid bilayer of organelles 
and cell membranes, as signalling molecules or to partake in myelination of nervous 
tissue, the majority of ingested lipids are stored in adipocytes or used immediately as 
a source of fuel (Stipanuk & Caudill, 2013). 
1.2.2 Protein and carbohydrate metabolism, and consequent effects on pro-
growth pathways  
In terms of protein metabolism, small peptides and single amino acids are yielded from 
mechanical and chemical digestion, and are absorbed through the intestinal border 
(Berg, et al., 2002). Once in the blood stream, amino acids are either used for protein 
synthesis, or for energy production by tissues that can utilise amino acids, such as the 
kidneys and intestines. The remainder are converted to glucose through the process 
of gluconeogenesis in the liver (Stipanuk & Caudill, 2013). 
Dietary carbohydrates are typically consumed in the form of starches and sugars, that 
is, polysaccharides and disaccharides. In the stomach and duodenum, mechanical 
and enzymatic breakdown occurs until monomers are yielded (Sherwood, 2010). 
Here, they can be absorbed across the intestinal border into circulation, where they 
bring about their glycaemic effect. While serum glucose is maintained homeostatically 
during the post-absorptive, or fasting, state at 4-5 mM, postprandial glucose levels 
usually peak at approximately 8 mM (American Diabetes Association, 2001). This rise 
in glucose above homeostatic levels triggers the release of insulin by the β-cells of the 
pancreas, so that the baseline insulin level of <174 pmol/L may rise to between 208 
and 1900 pmol/L during the postprandial period (Melmed, et al., 2016). It should be 
noted that amino acids from protein digestion may also elevate insulin levels, but that 
this effect is more modest than that of carbohydrates. Notably, the rise in serum insulin 
stimulates the production of insulin-like growth factor 1 (IGF-1) in the liver (Cangemi, 
et al., 2016). This rise in insulin and IGF-1 favours anabolic pathways and facilitates 
protein synthesis, cell growth and proliferation (Cangemi, et al., 2016). Furthermore, 




prevents the release of free fatty acids and monoacylglycerides from adipocytes into 
circulation, making them less available for metabolic processes (Sherwood, 2010). 
On a cellular level, phosphatase-and-tensin homologue (PTEN) keeps insulin receptor 
substrates 1 and 2 (IRS1/2) inactive through inhibition in the absence of insulin 
binding. However, during postprandial conditions, insulin binds to its receptor, resulting 
in the phosphorylation and activation of IRS1/2 (Cantley, 2002; Hemmings & 
Restuccia, 2012). This allows binding from phosphatidyl-inositol 3-kinase (PI3K), a 
central and fundamental regulator of cellular survival, growth and proliferation 
(Cantley, 2002). The result of PI3K’s activity is the recruitment and activation of 
pyruvate dehydrogenase kinase 1 (PDK1) and protein kinase B (PKB), also known as 
Akt. This consequently inhibits AS160, thereby lifting the inhibition of glucose 
transporter 4 (GLUT4) translocation. These transporters are then able to embed 
themselves in the cell membrane and facilitate glucose entry (Cantley, 2002). Insulin 
also activates hexokinase, the first enzyme in the glycolytic pathway. Hexokinase is 
responsible for the conversion of glucose to glucose-6-phosphate. This reduces the 
intracellular glucose concentration thereby promoting additional glucose uptake 
(Stipanuk & Caudill, 2013).  
 




Ultimately, the systemic and intracellular responses during the postprandial period 
result in the reduction of serum glucose through the uptake of glucose into cells for 
utilisation or storage (Cantley, 2002).  
1.2.3 Metabolic flexibility and the production of ATP 
Considering the competitive effect between metabolites, it should be noted that most 
physiological tissues can use either glucose or lipids in some form or another. With 
the exception of the retina, renal medulla and erythrocytes, which are all obligatory 
glycolytic cells, all other tissues can utilise fuel sources other than glucose. The brain, 
skeletal muscle, adipose tissue, intestine and kidneys all show a strong preference for 
glucose but can rely on alternate fuels when glucose availability is insufficient (Berg, 
et al., 2002). The brain can utilise ketone bodies produced by the liver during starvation 
and, to a much lesser extent, lactate. Skeletal muscle is able to consume free fatty 
acids, triacylglycerols, branched-chain amino acids (BCAA) and lactate. Adipose 
tissue can catabolise triacylglycerols for energy, the intestine can use glutamine, and 
the kidney free fatty acids, ketone bodies, lactate and glutamine. Thus, the majority of 
tissues are able to switch between lipolytic and glycolytic pathways (Mahan, et al., 
2012). 
Regardless of the preferred metabolite, the ultimate goal of catabolism is the 
production of adenosine triphosphate (ATP) to power cellular processes. When 
glucose is the preferred metabolite, degradation occurs through one of two pathways 
– aerobic or anaerobic (Sherwood, 2010). Both pathways share a common entry point, 
namely glycolysis, whereby glucose is converted through a series of enzymatic 
reactions in the cytoplasm to form pyruvate (Sherwood, 2010). After glycolysis, the 
anaerobic and aerobic pathways diverge. During anaerobic respiration, which is 
usually only favoured in the absence of oxygen, pyruvate is converted to lactate. This 
process is considerably less efficient than the aerobic pathway as it produces only two 
ATPs per molecule of glucose, while the latter produces approximately 38 (Sherwood, 
2010). Additionally, the lactate yielded by the anaerobic pathway would need to be 
removed from the cell and transported to the liver before any further metabolic 
advantage is reached (Berg, et al., 2002).  
Notably, ATP can also be produced from fatty acids. When the need arises, fatty acids 




1 (CPT-1) into the mitochondria. Once inside, the fatty acid undergoes beta-oxidation, 
a process whereby pairs of carbon atoms are cleaved to produce acetyl-CoA. These 
acetyl-CoA molecules are then shuttled into the tricarboxylic acid (TCA) cycle as the 
pathway converges with that of glucose oxidation, resulting in the production of ATP 
(Stipanuk & Caudill, 2013). 
 
1.3  Metabolism and molecular pathways during starvation 
 
1.3.1 Acute starvation and endogenous energy sources 
After the postprandial period, which lasts approximately two hours in duration, serum 
glucose begins to fall as exogenous sources have been fully utilised. However, it is 
essential that serum glucose be maintained at homeostatic levels, especially for the 
survival and functioning of obligatory glycolytic cells. Thus, as serum glucose begins 
to fall, so too does the production and secretion of insulin by the pancreatic β-cells, as 
mediated by negative feedback (Berg, et al., 2002). With serum insulin now at modest 
levels, the inhibition of glycogenolysis is reversed. Glucagon is produced and released 
by pancreatic α-cells, which allows glycogen to be catabolised to provide the body with 
glucose. While there can be substantial amounts of glycogen stored in the liver and 
muscle tissues, these stores are not interminable and are often depleted within 18-24 
hours of starvation. The body is thus tasked with finding an alternative source of 
glucose, and its next resort is to initiate muscle catabolism and gluconeogenesis 
(Mahan, et al., 2012). During this stage of starvation, the upregulation of catabolic 
hormones involved in glycogenolysis becomes even more evident, and the breakdown 
of skeletal muscle commences. Cortisol and catecholamines, like epinephrine and 
norepinephrine, instigate skeletal muscle catabolism in order to release amino acids 
into the blood stream. These metabolites are transported to the liver and kidneys 
where they are deaminated and converted to α-ketoglutarate and pyruvate, then to 
oxaloacetate, and, eventually, to glucose (Mahan, et al., 2012). This process, 
however, is metabolically demanding and unsustainable, as muscle tissue is 
necessary to sustain basic functions, such as breathing, digestion and cardiac output. 




would prove detrimental, and after 24-48 hours, adaptive metabolic shifts occur to 
enable lipid stores to be utilised (Stipanuk & Caudill, 2013).  
1.3.2 Adaptations to long-term starvation 
Due to the lower levels of serum insulin, hormone-sensitive lipase is relieved from its 
inhibition. Fatty acids are cleaved from triglycerides within adipocytes and are released 
into the blood stream to act as the predominant source of energy. Skeletal and cardiac 
muscle cells, liver tissue and adipocytes all switch to lipolytic pathways, rather than 
glycolytic ones, and beta-oxidation becomes the main source of acetyl-CoA for ATP 
production within those cells (Stipanuk & Caudill, 2013). 
Although the shift to lipids as a fuel source for metabolically flexible tissues reduces 
the need for glucose, it is not sufficient to prevent significant muscle loss. The brain 
and nervous system still require 110-120 g of glucose per day for adequate 
functioning, which equates to 160-200 g of protein, or approximately 1 kg of muscle 
tissue (Mahan, et al., 2012). If this were to continue, the effects would be devastating 
as not only skeletal muscle, but cardiac and smooth muscle would begin to waste. As 
a last resort, and in accordance with the pro-lipolytic metabolic profile, ketogenesis 
commences to provide the brain with an alternate fuel source (Berg, et al., 2002). 
Through this, the consumption of glucose is reduced, and ketones provide a suitable 
substitute for 80% of the glucose previously required by the brain and nervous system. 
The remaining 20%, along with the glucose needed to sustain obligatory glycolytic 
cells, represent the only portion of glucose consumption for which there can be no 
substitute. Notably, much of this is synthesised from the glycerol backbone of 
triglycerides released during lipolysis, and amino acids, in almost equal proportions 
(Berg, et al., 2002). 
By this stage, the body has made its final metabolic adaptation, and, provided fluid 
intake is sufficient, this may endure for several days. However, although this is much 
more sustainable than previous stages of starvation, is still only expected to be 







1.4  Intracellular adaptations to starvation 
 
1.4.1 Intracellular metabolic signalling pathways 
As macronutrients become scarce, systemic changes, such as those listed above, 
enable survival through both acute and chronic starvation. However, there are also 
several intracellular mechanisms which enable this adaptation to take place, enabling 
cellular energetics to compensate for metabolic stress. 
Firstly, nutrient deprivation, in the form of a high AMP/ATP ratio is sensed by a protein 
known as liver kinase B1 (LKB1). As the name suggests, this protein is abundant in 
liver hepatocytes, but is found in cells throughout the body. LKB1 activates 5’-AMP-
activated protein kinase (AMPK), which is known as the “nutrient sensor” of the cell 
and the master regulator of energy metabolism (Kuhajda, 2008). AMPK activates unc-
51-like kinase 1 (ULK1), a protein required for the formation of pre-autophagosomes, 
which is discussed in more detail below. Additionally, AMPK phosphorylates and 
inactivates the mammalian target of rapamycin (mTOR), consequently lifting the 
inhibition on autophagy and preventing protein synthesis (Mizushima & Komatsu, 
2011). Furthermore, AMPK also stimulates adipose triglyceride lipase (ATGL), which 
enables the cleavage of fatty acids from triglycerides within adipocytes and prevents 
fatty acid synthesis. Overall, AMPK mobilises existing cellular stores to release 
metabolites to correct the AMP/ATP ratio, thereby restoring homeostasis to 
intracellular energetics (Kuhajda, 2008). 
Another pathway implicated in the cellular response to starvation is that of PI3K and 
Akt. During the fed state, extracellular insulin signalling leads to the activation of 
IRS1/2, and consequently, PI3K and Akt (Hemmings & Restuccia, 2012) This favours 
anabolic pathways, such as glycogen synthesis, fatty acid synthesis and protein 
synthesis. In the absence of insulin signalling, PI3K and Akt are downregulated, along 
with their downstream targets, such as mTOR (Hemmings & Restuccia, 2012). Thus, 
during starvation, mTOR activity is dampened, both by the activation of AMPK and the 
inactivation of Akt. The result is the inhibition of protein synthesis and the upregulation 






1.4.2 Types of autophagy, autophagic pathways and functions 
Three different types of autophagy exist, all of which employ lysosomal activity to 
degrade intracellular proteins (Glick, et al., 2010). Chaperone-mediated autophagy 
involves the escorting of target proteins by chaperone proteins to the lysosome for 
degradation (Mizushima & Komatsu, 2011). In micro-autophagy, the lysosomal 
membrane forms an invagination to take up proteins from the cytosol directly. 
However, the majority of protein degradation and recycling is owed to macro-
autophagy – a sort of “bulk” degradative system (Singh & Cuervo, 2012). 
Macro-autophagy (hereafter referred to as “autophagy”) refers to the intracellular 
degradation of proteins and organelles through a highly organised and conserved 
pathway involving autophagosomes (Mizushima & Komatsu, 2011). Autophagy is 
induced by a variety of stressors, such as cellular and endoplasmic reticulum stress, 
hypoxia, radiation, high temperatures, toxic compounds, and most notably, nutrient 
deprivation. Under these conditions, and in response to a high AMP/ATP ratio and 
consequent AMPK signalling, the stimulus for autophagy is received (Mizushima & 
Komatsu, 2011). 
Despite being a process employed to degrade existing proteins, the process of 
autophagy begins in the endoplasmic reticulum with the synthesis of proteins 
necessary for the formation of pre-autophagosomes (Glick, et al., 2010). These 
include ULK1, autophagy related protein 13 (Atg13), Atg101 and Fip200. These 
proteins, along with a cup-shaped section of membrane, bud off the endoplasmic 
reticulum to form the pre-autophagosome. As this grows and matures, Beclin 1 is 
added and activated through phosphorylation by ULK1. In this state, Beclin 1 is able 
to phosphorylate phosphatidylinositol 4,5-bisphosphate (PIP2) to phosphatidylinositol 
3,4,5-trisphosphate (PIP3), similar to the actions of PI3K (Mizushima & Komatsu, 
2011). The increased ratio of PIP3 to PIP2 results in the downstream recruitment of the 
ubiquitin-binding protein p62 and microtubule-associated protein 1A/1B light chain 3B-
I (LC3-I). Another protein complex, consisting of Atg5, Atg16 and Atg12, is added to 
the membrane of the pre-autophagosome. LC3-I is converted to LC3-II through the 
addition of phosphatidylethanolamine during the extension of the phagophore, and this 
indicates autophagosomal maturation. By the time the autophagosome has fully 




autolysosome (Glick, et al., 2010). Along with other proteins, Rab7 facilitates the 
binding of the membranes and the fusing of these two organelles – the end goal being 
intracellular digestion. Once inside the autolysosome, proteins undergo acidic and 
enzymatic degradation (Singh & Cuervo, 2012).  
 
Figure 1.3: The formation of the autophagosome and fusion with the lysosome (Mizushima & Komatsu, 
2011). 
The ultimate purpose of autophagy is to make provision during nutrient stress and to 
remove unwanted proteins and/or organelles (Singh & Cuervo, 2012). However, in the 
event that metabolic homeostasis cannot be reached, and the cell experiences more 
significant nutrient stress, the cell is forced to resort to more extreme measures, such 
as cell cycle arrest. 
1.4.3 The cell cycle and growth arrest 
Many cell types, such as neurons, adipocytes and myocytes, do not undergo mitosis 
after fully differentiating, and exist in the growth zero or gap zero phase (G0) (Terzi, et 
al., 2016). This refers to a state wherein the cells remain viable and metabolically 




1998). The G0 phase also includes cells that are in a quiescent state, which may be 
described as a “reversible, non-proliferating state” (Yao, 2014). Tissues that require 
mitotic cell division for regenerative purposes only may contain many cells in G0, which 
may re-enter the cell cycle to produce additional daughter cells when needed (Yao, 
2014). 
However, apart from quiescent or terminally differentiated cells, most other cells in the 
body pass through the cell cycle and undergo mitotic cell division (Blagosklonny, 
2011). The cell cycle consists of several, distinct phases: During the first gap phase 
(G1), which follows immediately after mitotic cell division, the cell produces proteins 
and organelles that are required for DNA synthesis. The G1 phase is followed by the 
synthesis phase (S), during which a complete copy of cellular DNA is produced 
(Cooper, 2000). The second gap phase (G2) is marked by additional growth and the 
reorganisation of intracellular structures as the cell begins to prepare for mitotic cell 
division (Cooper, 2000). The first gap phase, synthesis phase, and second gap phase 
are collectively known as “interphase” – the first, and longest, stage of mitotic cell 
division. The end of the second gap phase signals the cessation of interphase, and 
mitosis (M) begins (Schafer, 1998).  
Several regulatory mechanisms exist to ensure controlled and appropriate cell 
division. These include negative and positive regulators of the cell cycle which allow 
progression through the checkpoints and facilitate transition between stages (Barnum 
& O’Connell, 2014). The former includes tumour suppressor proteins such as 
retinoblastoma protein (Rb), p53 and p21 (Terzi, et al., 2016). These can induce cell 
cycle arrest, often by inhibiting the positive regulators to prevent passage between 
stages (Blagosklonny, 2011). On the other hand, the cell cycle is positively regulated 
by the expression and degradation of four main cyclins which bind to the relevant 






Figure 1.4: The relative intracellular expression of cyclins in each stage of the cell cycle (Schafer, 1998). 
For a cell to progress through a checkpoint, the negative regulators of the cell cycle 
must be absent or inactive while the positive must be present and active (Barnum & 
O’Connell, 2014). Rb, for example, is typically bound to E2 transcription factor (E2F), 
which, when unbound, promotes the transcription of proteins that facilitate the G1/S 
transition (Yao, 2014). In order for the cell to progress to the S phase, Rb must be 
inhibited to reverse its suppression of E2F (Yao, 2014). This is accomplished by the 
complexes formed between cyclin D and both CDK4 and CDK6, as well as cyclin E 
and CDK2. E2F then promotes the upregulation of cyclin A, allowing the cell to pass 
through the G1/S checkpoint and enter into the S phase. This will only occur if the cell 
meets the criteria for this checkpoint, as it is assessed for adequate size, nutrient 
availability and DNA integrity (Terzi, et al., 2016). 
In the nucleus, cyclin A-CDK2 complexes initiate DNA replication, and the cell enters 
the G2 phase upon completion. At the end of the G2 phase, this DNA is examined, and 
the cell passes through the G2 checkpoint (Barnum & O’Connell, 2014). However, if 
the DNA is damaged or incomplete, the cell may undergo temporary cell cycle arrest 
to repair or complete its DNA (Bar-On, et al., 2007). 
During the third checkpoint, which occurs during the metaphase of mitosis, the cell is 
checked for the appropriate attachment of the sister chromatids to spindle 




al., 2019). Dysregulation of the cell cycle is commonly observed in cancer cells, 
resulting in uncontrolled mitotic cell division (Sun, et al., 2014). Not only do cancer 
cells have an infamously high rate of cell division, but poor control over the progression 
between stages resulting in the resistance of both cell cycle arrest and senescence 
(Sun, et al., 2014). While benign cultured cells have been reported to enter growth 
arrest in response to starvation (Schafer, 1998), the effect of starvation on cancer cells 
is much less clear. 
 
Figure 1.5: Phases of the cell cycle, and associated cyclins and CDKs (Schafer, 1998). 
Besides growth arrest as a consequence of starvation, DNA damage or mutation may 
also cause cells to arrest the cell cycle for the purpose of repair. However, if the DNA 
damage is severe, or cells cannot progress through the cell cycle, they become 
stressed and may induce apoptosis (Caccuri, et al., 2019). 
 
1.4.4 Apoptotic triggers, pathways, and mechanisms 
Apoptosis may be described as an organised and highly conserved process of 
programmed cell death (Savitskaya & Onishchenko, 2015). This occurs in a wide array 
of circumstances and is essential to maintain normal physiological functioning and 
ensure survival. For instance, apoptosis ensures survival by eradicating old and 




pathogens and those showing cancerous activity (Elmore, 2007). This helps the body 
to regulate immune functioning, to prevent the spread of infection, to eradicate 
malignancies and to function optimally as the quality of cells are maintained. Apoptosis 
may be divided into three continuous steps, with the start of the process depending 
entirely on the cause of initiation (Elmore, 2007). 
1. Initiation: this is the first step of apoptosis, and may be initiated through one of 
two pathways: 
a. Extrinsic pathway: As the name suggests, the extrinsic pathway is activated 
by the binding of extracellular tumour necrosis factor α (TNFα) and Fas-
ligands to receptors on the cell surface. TNFα is a cytokine produced by 
activated macrophages, natural killer cells and CD4+ cells, while Fas-ligands 
are found on the surfaces of T-lymphocytes (Savitskaya & Onishchenko, 
2015). Upon binding, the stimulated receptor in the cell membrane activates 
an intracellular death domain. The consequent recruitment and activation of 
Fas-associated death domain (FADD) leads to the cleavage and activation of 
pro-caspase 8, which, in turn, leads to the activations of caspase 3 and the 
self-amplifying caspase cascade (Elmore, 2007). 
b. Intrinsic pathway: When homeostasis within the cell is severely disrupted and 
recovery is unlikely, as in the case of severe nutrient stress or hypoxia, the 
mitochondria sense this disruption, and the mitochondrial membrane 
becomes permeabilised. Similarly, if the cell experiences DNA damage 
beyond repair, p53, a potent tumour suppressor, is activated, resulting in the 
mobilisation of Bcl-2-associated X protein (BAX) in the cytosol. BAX and Bcl-
2 homologous antagonist killer (BAK) are pro-apoptotic proteins that are 
bound to anti-apoptotic proteins, such as B-cell lymphoma 2 protein (BCL-2) 
and B-cell lymphoma-extra large (BCL-xL), under normal circumstances 
(Savitskaya & Onishchenko, 2015). Should p53 induce the intrinsic pathway, 
and pro-apoptotic signals exceed that of anti-apoptotic signals, these proteins 
are released and form channels in the mitochondrial membrane. Following 
permeabilisation of the mitochondrial membrane, cytochrome C leaches out 
of the mitochondria and is free to bind to apoptotic protease activating factor 
1 (APAF1) and pro-caspase 9 to form the apoptosome in the cytosol. This 




(initiator caspase) and converging with the extrinsic pathway through 
cleavage of the effector caspases (Elmore, 2007). 
2. Execution: After initiation by the extrinsic or intrinsic pathways, caspase 3 is 
cleaved, which, in turn, cleaves poly (ADP-ribose) polymerase, or PARP. This 
is a DNA repair enzyme that, when cleaved, can no longer carry out its function 
(Savitskaya & Onishchenko, 2015). The immobilisation of PARP allows DNA 
fragmentation to occur, while endonucleases and proteases degrade 
cytoskeletal proteins, resulting in cellular degradation. By this stage, the cellular 
morphology typically represents apoptosis as shrinkage, pyknosis, karyorrhexis 
and the formation of apoptotic bodies is observed (Elmore, 2007). 
3. Phagocytosis: The final step in apoptosis involves only the removal of apoptotic 
bodies by phagocytic cells. This is stimulated by the presentation of ligands on 
the cell membrane for phagocytic binding (Savitskaya & Onishchenko, 2015). 
 
Figure 1.6: The convergence of apoptotic pathways (Rampal, et al., 2012) 
Despite the negative connotations carried by the concept of cell death, apoptosis is 




were permitted to survive (Savitskaya & Onishchenko, 2015). However, cancer cells 
are able to evade this programmed cell death through multiple adaptive mechanisms. 
These may include the downregulation and upregulation of pro-apoptotic and anti-
apoptotic genes, respectively; through the production of growth factors; and by 
ensuring a consistent and adequate nutrient supply (Rampal, et al., 2012). 
 
1.5  Cancer metabolism and hallmarks of cancer 
 
1.5.1 Procurement of glucose and growth signals 
To avoid metabolic stress and unnecessary cell death, the majority of tissues regulate 
glucose homeostasis through the intelligent co-ordination of several mechanisms. 
Cancer cells, on the other hand, surpass this, in their nearly aggressive procurement 
of glucose. Firstly, benign cells express appropriate quantities of the relevant insulin 
receptors (IRs) on their cell membrane, which mediate the controlled influx of glucose 
into insulin-dependent tissues. However, several studies demonstrate an 
overexpression of IRs on malignant cell surfaces (Frasca, et al., 2008). Up to 80% of 
breast cancers express above-average levels of IRs. Furthermore, up to 20% show as 
much as a ten-fold increase in IR expression (Frasca, et al., 2008).  
Secondly, GLUTs in benign cells are specifically expressed to sustain the needs of the 
cell. However, in cancer cells, overexpression of several types of GLUTs have been 
reported in various malignancies (Adekola, et al., 2012). In addition to GLUT4, an 
insulin-dependent GLUT, the insulin-independent GLUT1-3 are expressed and ensure 
unlimited and unconditional uptake of glucose (Adekola, et al., 2012). These 
adaptations in receptors and glucose transporters represent only two mechanisms 
whereby malignant tissues ensure a constant supply of glucose, with additional 
adaptations existing within the cell. 
1.5.2 Hypermetabolism and de novo synthesis of biomolecules 
On an intracellular level, cancer is unusually metabolically active, and has an 
exceptionally high consumption rate of nutrients for its relative tissue size (Cathcart, 




exceptionally high rates of glucose uptake, which in turn, accounts for its high levels 
of utilisation (Cathcart, et al., 2017).  
Once inside, there are two potential metabolic fates for the plethora of glucose 
molecules flooding into the cell: de novo synthesis of other metabolites, or utilisation 
for energy (Cathcart, et al., 2017). For cancer cells to sustain their dynamic level of 
functioning, growth and replication, all sorts of macromolecules are needed: glucose, 
lipids, nucleic acids and amino acids. These molecules are used, not only for energy, 
but to provide structural components for malignant cell division (Longo & Fontana, 
2009). New nucleic acids and amino acids may be synthesised from the abundance 
of glucose within the cell and organised into new strands of DNA and proteins, 
respectively; synthesised lipids may be used to form new cell membranes and 
organelles. Ultimately, the modus operandi of cancer cells is to divide and conquer the 
surrounding microenvironment, while intracellular metabolic pathways must make 
provision for this (Longo & Fontana, 2009). 
1.5.3 The Warburg Effect in cancer 
Besides the shuttling of glucose molecules into pathways for the de novo synthesis of 
macromolecules, glucose metabolism in cancer is notoriously counterintuitive. In 
hypermetabolic cells, optimal use of glucose to obtain the maximum number of ATP 
per molecule would be expected. This is, however, not always the case in cancer cells. 
The infamous Warburg Effect was described as early as the 1920’s, wherein cancer 
cells utilise glucose, not through oxidative pathways, but through what is described as 
“anaerobic glycolysis” – glycolysis and the conversion of pyruvate to lactate, even in 
the presence of oxygen (Bonucelli, et al., 2010). This favouring of anaerobic 
respiration is metabolically inefficient because, as previously described, the process 
yields only two molecules of ATP per glucose, while aerobic respiration holds the 
potential for approximately 38 (Stipanuk & Caudill, 2013). 
However, despite the metabolic inefficiency of this pathway, it is postulated to offer a 
survival advantage to the tumour cells beyond that of ATP production. Interestingly, 
some research indicates that lactate may support tumour growth and metastasis 
(Bonucelli, et al., 2010). Additionally, the production of lactate yields hydrogen ions, 
and when this is expelled from the cell, it can be used to acidify the extracellular matrix. 




and enables invasion for further growth of the solid tumour (Kato, et al., 2013). In 
addition, degradation of the surrounding structure aids in the development of additional 
vasculature – a process known as angiogenesis (Kato, et al., 2013). This is essential 
to maintain continual tumour growth, as parts of the tumour are far from an adequate 
blood supply. The proximity of the tumour to vasculature also enables metastasis, or, 
the spreading of malignant cells from its original site to distal sites around the body 
(Kato, et al., 2013). Ultimately, this abnormal and counterintuitive selection for 
anaerobic glycolysis, and the consequent yielding of lactate, may convey several 
advantages to the tumour itself. Indeed, high lactate levels have been correlated with 
increased tumour aggression, metastasis, tumour recurrence and a poorer prognosis 
in patients (Kato, et al., 2013). 
1.5.4 Altered metabolic signalling and levels of autophagy in cancer cells 
In terms of signalling pathways, several studies have reported mutations in pro-
survival genes in a wide array of human cancers (Kuhajda, 2008; Yuan & Cantley, 
2008; Courtney, et al., 2010). This can result in significant over- or under-expression 
of specific functional proteins, enabling increased cell survival, growth and 
proliferation. Besides adaptations in insulin and IGF-1 receptors, many tumours show 
independent adaptations in the PI3K/Akt pathway, with both the former and the latter 
being overexpressed in several cancer cell lines (Yuan & Cantley, 2008; Courtney, et 
al., 2010). Additionally, PTEN, a potent tumour suppressor gene, is often mutated in 
tumours, rendering it partially or completely dysfunctional (Yuan & Cantley, 2008). 
Similarly, AMPK, along with LKB1, is often downregulated too, preventing adequate 
regulation of cellular metabolism, and apoptotic cell death (Kuhajda, 2008). Ultimately, 
these mutations are advantageous to the cancer cell as it allows the evasion of cell 
death and assists in cell growth and replication. 
Autophagy, which lies downstream of the PI3K/Akt pathway, is strongly suggested to 
play a protective role against tumourigenesis (Glick, et al., 2010; Mizushima & 
Komatsu, 2011). Additionally, defective autophagic genes may promote the 
development of malignant tumours (Qu, et al., 2003). However, once a tumour is 
established, autophagy seems to play a protective role against cancer cell death, 
buffering the cells from various stressors. While there has been controversy 




upregulation of autophagy in malignant cells to aid in the provision of intracellular 
substrates, and that the inhibition of autophagy promotes cell death (Mizushima & 
Komatsu, 2011; Leisching, et al., 2014; Jung, et al., 2017; Jiang, et al., 2018; 
Rupniewska, et al., 2018). Furthermore, high levels of autophagy have been correlated 
with tumour aggressiveness and metastasis (Lazova, et al., 2011; Yao, et al., 2016; 
Zhu, et al., 2019). However, this may vary between cancer types and stages, 
especially in a clinical setting (Glick, et al., 2010). 
Considering that cancer cells display unique metabolic hallmarks, it would suffice to 
assume that it may also harbour unique metabolic vulnerabilities. Cancer is 
significantly more metabolically active, and therefore has greater nutrient 
requirements. Cancer cells also display a greater dependence on glucose, not only for 
survival and proliferation, but for the degradation of surrounding tissues for invasion 
as well. Thus, investigation into the behaviour of cancer in the absence of sufficient 
nutrients is warranted. 
 
1.6  Caloric restriction, intermittent fasting and cancer 
 
1.6.1 Caloric restriction for the prevention of chronic diseases 
Over the past few decades, there has been increasing interest in the field of caloric 
restriction (CR). This may be defined as a reduction in dietary intake without causing 
malnutrition (O’Flanagan, et al., 2017). In essence, this ensures that the body does 
not meet its caloric requirements, but without causing a significant loss of lean body 
mass. This can be achieved through a number of means: through consistent caloric 
restriction, where an individual is not restricted in terms of when they may eat, but 
rather, by food quantity; intermittent fasting (IF), also known as short-term starvation 
(STS), where the quantity of food is not restricted, but rather when food may be 
consumed; or a combination of both. In other words, consistent CR represents a 
reduction in daily caloric intake over extended periods of time, where STS is the 
complete elimination of caloric intake over shorter periods of time (Longo & Fontana, 
2009).  
CR has long been established as a powerful strategy for the prevention of chronic 




neurodegenerative diseases (O’Flanagan, et al., 2017). This has been well-
documented in both pre-clinical and observational human studies (Longo & Fontana, 
2009; Cangemi, et al., 2016; Hanjani & Vafa, 2018). CR also offers the potential to 
extend lifespan, delay premature aging and to improve immunity and overall 
physiological functioning (O’Flanagan, et al., 2017). 
While the effect of CR on cancer prevention has been well-documented in animal 
models (James, 1994; Stewart, 2005; Carver, 2011; Moore, 2012; Lanza-Jacoby, 
2013), more research is needed to validate this effect in humans. Furthermore, chronic 
CR is deemed inappropriate as a clinical intervention. During critical illness, the body 
enters a catabolic and cachexic state, and chronic CR may exacerbate this. 
Additionally, chronic CR requires an extended period of time for results to be achieved, 
making it unsuitable to an acute, clinical setting. 
1.6.2 Short-term starvation in the context of cancer 
Consequently, as of late, there has been deepening interest in the potential for STS 
to impair cancer cell growth. Cancer, as a metabolically hyperactive tissue with high 
energy requirements may prove especially vulnerable when deprived of these 
nutrients – more so than non-malignant tissues. Furthermore, during STS, serum 
glucose remains at homeostatic levels and does not peak as it would during the 
postprandial period (Cangemi, et al., 2016). Consequently, insulin and accompanying 
growth factors, such as IGF-1, also remain low. This could render malignant tissues 
not only undernourished, but under-stimulated as well. This reduction in insulin-
derived stimulation could further result in core proliferation pathways, such as PI3K, 
being somewhat dampened (Raffaghello, et al., 2008). Further downstream, this 
reduction in dietary and caloric intake would likely result in the upregulation of 
autophagy.  As previously mentioned, autophagy seems to have a dual role in cancer 
cells, with various studies implicating increased autophagic flux with both decreased 
and increased cell viability, depending on the cancer type (Kounakis, et al., 2019).  
In terms of substrates available during the fasting state, glucose availability declines 
between 24 and 48 hours into fasting and lipids become increasingly abundant. While 
many cancers can utilise fatty acids, they are less metabolically efficient in a hypoxic 
setting and are converted to other macromolecules with greater difficulty. Additionally, 




glucose is slightly diminished. Ketones are thought to inhibit cancer cell growth for the 
following reasons: Firstly, many, if not most cancer tissues rely largely on glucose for 
energy and macromolecule biosynthesis and cannot use ketones for the same ends 
(Poff, et al., 2014). Secondly, ketones cannot be converted to lactate, and may thus 
compromise local invasion and metastasis by preventing the acidification of the 
extracellular matrix (Poff, et al., 2014). Thirdly, if some degree of glycolysis were to 
continue, even in a ketotic state, the presence of ketones may cause lactate 
accumulation within the cell and hamper cellular functioning in tumour tissue. Ketones 
enter the cell through the same transporter that is used to export lactate from the cell 
– the monocarboxylate transporter (MCT). Therefore, the uptake of ketones may 
compromise the export of lactate out of the cell (Poff, et al., 2014).  
As previously described, circulating growth signals are reduced during STS, and while 
most cancers do not rely on external cues alone to grow and replicate, many normal 
tissues consider this a cue to reduce their metabolic activity (Raffaghello, et al., 2008). 
In this case, non-malignant tissues may attempt to conserve resources, and diminish 
the proportion of energy dedicated to growth and replication. Rather, pathways aimed 
at survival and repair would be favoured in normal cells, while malignant cells continue 
to proliferate. This difference in response to starvation forms the basis of two 
treatment-related phenomena, known as Differential Stress Resistance (DSR) and 
Differential Stress Sensitisation (DSS) (Buono & Longo, 2018). DSR describes the 
enhanced protection that normal cells experience from chemotherapy-induced 
cytotoxicity because of the starvation-induced reduction in metabolic activity (Buono 
& Longo, 2018; De Groot, et al., 2019). DSS, on the other hand, refers to the enhanced 
efficacy of chemotherapy in killing malignant cells. This is owed to the cumulative 
stress placed on them by nutrient deprivation in conjunction with chemotherapeutic 
insult (Buono & Longo, 2018; De Groot, et al., 2019). Current in vitro and in vivo 
research is limited but has confirmed these phenomena in several cancer cell lines. 
1.6.3 Previous studies investigating the effect of starvation on 
chemosensitivity 
D’Aronzo, et al. (2015) demonstrated the effect of fasting cycles on the efficacy of 
gemcitabine, a chemotherapeutic agent used to treat malignant tumours of the 




reduced glucose (0.5 g/L rather than 1.0 g/L) and foetal bovine serum (FBS) (1% rather 
than 10%) to mimic starvation conditions, the authors investigated various outcomes 
on three pancreatic cancer cell lines. While gemcitabine alone had no significant effect 
on the cell cycle, a 24-hour starvation period prior to gemcitabine treatment 
significantly increased the proportion of cells in the G0/G1 phase and reduced the 
percentage of cells in the S and G2/M phase (D’Aronzo, et al., 2015). Cell death was 
also highest in the combination group, successfully sensitising all three cell lines to the 
drug. These findings were further confirmed by an in vivo study, where mice that 
received pancreatic cancer xenografts displayed a 40% reduction in tumour growth 
when they received gemcitabine injections after 24 hours of fasting compared to that 
of the drug alone (D’Aronzo, et al., 2015). 
A similar increase in chemosensitivity was observed in mouse, rat and human glioma 
cell lines, but not in primary mouse glial cells, when cells were cultured in starvation-
mimicking media for 24 hours prior to treatment with temozolamide (Safdie, et al., 
2012). Using both a subcutaneous and intracranial mouse model, Safdie, et al. (2012) 
investigated the effect of a 48-hour fasting period on the efficacy of temozolamide. 
While the drug alone was able to significantly slow tumour progression when 
compared to the control mice, the combination group (fasting + temozolamide) had 
significantly reduced tumour volumes at the 28-day endpoint, even when compared to 
the treatment group. The authors attributed this largely to the reduction in serum 
glucose and IGF-1 following the induction of a starvation period (Safdie, et al., 2012).  
Raffaghello, et al. (2008) examined the effects of starvation prior to cyclophosphamide 
treatment on primary rat glial cells, as well as on one human and four rat glioma cell 
lines, and one human neuroblastoma cell line. While only 20% of glial cells in the 
control group survived the cyclophosphamide treatment, 80% of pre-starved glial cells 
showed resistance (Raffaghello, et al., 2008). Conversely, starvation did not offer 
protection in the cancer cell lines but reduced the resistance of the RG2 glioma cells 
to treatment. An in vivo study corroborated these findings with only 57% of control 
mice surviving a high-dose administration of etoposide, while the mice starved for 48 
hours prior to treatment attained a significantly greater viability of 94% (Raffaghello, et 
al., 2008). Interestingly, although starvation caused the mice an approximate 20% loss 
in body mass, the majority of the weight was regained within four days of receiving 




toxicity. Non-starved mice, in turn, lost 20% of their body mass in response to the 
chemotherapy while the starved mice were recovering theirs. This suggests the partial 
protection of non-malignant tissues from chemotoxicity (Raffaghello, et al., 2008). 
Nearly identical findings were reported by Bianchi, et al. (2015) illustrating the 
increased sensitivity of colon cancer cell lines to oxaliplatin, both in vivo and in vitro 
when preceded by at least 24 hours of starvation (Bianchi, et al., 2015).  
More specific to breast cancer, a study by Lee, et al. (2012) involved the culturing of 
a murine breast cancer cell line in medium supplemented with serum from mice that 
were either fed or fasted for 48 hours. Consequently, cancer cells were significantly 
more susceptible to chemotherapy-induced cell death when treated with serum from 
fasted mice than those from fed mice (Lee, et al., 2012). Additionally, when 17 
mammalian cancer cell lines were treated with either normal or starvation-mimicking 
media, 15 showed increased sensitivity to chemotherapeutic agents. These results 
were confirmed in vivo as subcutaneous allografts with four of the eight cancer cell 
lines also showed significantly greater chemosensitivity when mice were starved prior 
to treatment (Lee, et al., 2012). 
In a similar study by Brandhorst, et al. (2013), mice were injected with either breast 
cancer or glioma cells from murine cell lines. Treatment involved either a fasting period 
of up to 60 hours (STS) or a 50% reduction in caloric intake for three consecutive days 
(CR), followed by high-dose intravenous injections of doxorubicin. When compared to 
the mice fed a standard chow, mice in the STS group had significantly greater survival 
rates 25 days post-injection (16% vs 89%). Those in the CR group had an 
approximately 50% survival rate by comparison (Brandhorst, et al., 2013). This 
supports the notion that CR, especially through STS, increases the resilience of 
peripheral tissues to chemotherapy. However, in this study, breast cancer tumours did 
not show increased chemosensitivity when combined with CR, and the effect of STS 
on chemosensitivity was not investigated (Brandhorst, et al., 2013). In contrast, 
Yakisich, et al. (2016) reported potentially opposing outcomes. Following prolonged 
serum starvation for periods of 7-12 days, breast and lung cancer cells became 
resistant to previously efficacious drugs, such as paclitaxel and colchicine (Yakisich, 
et al., 2016). However, this is not currently supported by additional in vitro or in vivo 




Currently, clinical studies investigating DSR and DSS are extremely limited. However, 
a case series report released in 2009 describes the experiences of ten patients who 
fasted voluntarily for periods of 48-140 hours prior to chemotherapy, and between five 
and 56 hours afterwards (Safdie, et al., 2009). None reported significant side effects 
from fasting besides hunger and light-headedness, while six patients reported reduced 
side-effects from chemotherapy, such as fatigue and gastrointestinal intolerance. 
Furthermore, tumour growth was monitored in six patients, and demonstrated that 
fasting did not compromise the efficacy of chemotherapy (Safdie, et al., 2009). While 
this study comprised of a small sample size, it may serve as a pioneering study to elicit 
future trials in this regard. 
1.6.4 Potential advantages and disadvantages of short-term starvation as an 
adjuvant therapy in cancer treatment 
In summary, based on in vitro and in vivo models, short-term starvation seems to not 
only slow tumour growth and progression, but also to enhance chemosensitivity in 
malignant cells, as well as to protect normal cells from chemotherapy-induced 
cytotoxicity. Small-scale observational studies have supported these claims but 
warrant further investigation. If future studies do, however, support and verify these 
preliminary findings, fasting, as an adjuvant therapy may hold several advantages. 
Firstly, it may protect patients from the harmful side effects of chemotherapy, 
improving quality of life during treatment and mitigating morbidity. Furthermore, it may 
also have the potential to protect patients from chronic side effects and complications, 
thereby diminishing long-term morbidity and mortality. If fasting proves to sensitise 
cancer cells to chemotherapy or radiation, this may impact the clinical outcome in 
several ways, depending on the stage of disease. For patients whose tumours are in 
early stages and whose prognoses are good, it may shorten the time to remission, or 
minimise the need for chemotherapy, whether in intensity or duration. Alternatively, for 
those with potentially poor prognoses and middle to late-stage disease, it may 
potentially increase progression-free survival.  
Finally, in terms of practicality as an adjuvant therapy, fasting is an affordable and 
accessible intervention that could be implemented globally. As it is something that the 
patient can implement with the necessary education and guidance, it places little to no 




staffing, resources, or funding, and would be accessible to patients attending any type 
of healthcare facility. Additionally, such an intervention requires little skill to implement, 
is reported to have minimal side effects, and can be terminated at any time with little 
to no risk to the patient. 
However, no intervention can be represented without highlighting the potential risks 
and concerns. Firstly, fasting for long intervals, such as 48-72 hours, may induce mild 
side effects, such as fatigue, inability to concentrate, and hunger pains (Safdie, et al., 
2009). The potential chronic side effects are however of greater concern, and may 
include weight loss, especially the loss of lean body mass as the body enters a 
catabolic and cachexic state. This has the potential to impair clinical outcomes, as 
cancer and the treatment thereof is already associated with malnutrition. However, the 
long-term consequences of fasting in combination with chemotherapy has not been 
established (Safdie, et al., 2009). Conversely, the potential exists for the reduction of 
gastrointestinal side effects post-treatment to allow for greater caloric intake 
afterwards, where the patient may compensate for the fasting period. 
Besides concerns regarding the side effects of fasting, patients may be reluctant to 
consider or initiate fasting, and may also find adherence problematic. Thus, 
sustainability in the long-term, especially for patients receiving frequent or long-term 
treatment, is questionable, and may not be acceptable in patients who are critically ill. 
Other patients for whom this intervention would not be suited may include children, the 
elderly, pregnant or breastfeeding women, patients who are already at-risk of 
malnutrition, and patients with existing metabolic conditions, such as T2DM. However, 
many of these challenges and concerns are not insurmountable, and may be 
outweighed by the potential benefits and promise that this regime holds. Patients could 
be screened to identify ideal candidates for fasting who are less at-risk for 
complications, thereby reducing the risk of malnutrition. Comprehensive information 
sessions could be offered to patients considering this therapy, outlining the potential 
beneficial effects or outcomes over the expected difficulties. This may facilitate 







1.7 Hypothesis, Aims and Objectives 
Cancer is currently responsible for one in six deaths worldwide, making it the second 
leading cause of death after cardiovascular disease (WHO, 2018). In the light of the 
potential benefit that short-term starvation may pose, and the need for investigation 
into whether all types of cancer would show this same benefit, we thought it fit to 
investigate the effect of STS on the growth, viability, and metabolism of cancer cells, 
as well as whether it offers any potential in the face of current treatment regimes. 
 
1.7.1 Hypothesis 
We hypothesise that a period of starvation prior to doxorubicin treatment will 
selectively enhance treatment efficacy in cancer cells, while offering protection to non-
malignant cells 
1.7.2 Aims 
In order to test the hypothesis, the study comprised of three main aims: 
• To explore the effect of starvation over time on intracellular signalling pathways, 
autophagic flux, cell cycle progression and cell viability. 
• To establish the effects of starvation, doxorubicin treatment, and the 
combination thereof on live cell number, cell viability and cell cycle progression. 
• To determine the effect of starvation on chemosensitivity in MCF-12A breast 
epithelial cells, as well as in BT-549 and MDA-MB-231 breast cancer cells. 
1.7.3 Objectives 
To achieve the aforementioned aims, our objectives included the following: 
• To utilise western blotting to quantify the relative protein expression of PI3K, 
total Akt and phosphorylated Akt. 
• To detect changes in autophagic flux through the use of western blotting (Atg5, 
p62 and LC3-II) and immunocytochemistry (quantification of the number of 
autophagosomes). 





• To perform WST1 viability assays to determine the effects of the treatments on 
cell viability. 
• To utilise flow cytometry with propidium iodide staining to establish the 
percentage of dead cells within each group, thereby confirming cell viability. 
• To perform a live cell count with trypan blue in order to determine the total 





Chapter 2: Methods and Materials 
 
2.1 Study design 
 
Figure 2.1: In vitro study design. 
A non-malignant breast epithelial cell line (MCF-12A) and two triple-negative breast 
cancer cell lines (BT-549 and MDA-MB-231) were starved for three different time 
periods, while the control cells were maintained under standard conditions. Metabolic 
signalling pathways (PI3K, Akt), markers of autophagy (Atg5, p62, LC3-II) and 
autophagic flux, cell cycle progression and growth arrest, and cell viability were 
assessed. Based on this data, an optimal time point was selected and served as the 
starvation period for the remainder of the study. Cells were then treated with 
doxorubicin, with or without a preceding starvation period, to establish the effect of 
starvation on chemosensitivity. This was determined by quantifying live cell number, 




2.2  Cell lines and conditions 
 
Figure 2.2: Typical morphology of a) MCF-12A, b) BT-549 and c) MDA-MB-231 cells under 10x 
objective, under normal conditions, and at approximately 80% confluence. 
 
2.2.1 Cell lines 
Three cell lines were utilised for the purpose of this study. MCF-12A breast epithelial 
cells, originally isolated from the mammary gland of a patient with no history of cancer, 
were used as the control cell line, demonstrating the effects of the treatments on non-
malignant cells. BT-549 cells, a triple-negative breast cancer (TNBC) cell line, were 
originally excised from the mammary gland of a patient with an invasive ductal 
carcinoma. A second TNBC cell line was employed, but with the distinguishing feature 
of mesenchymal-like (as opposed to epithelial) characteristics. The MDA-MB-231 cell 
line originates from a patient with a metastatic adenocarcinoma of the breast; the cell 
sample was sourced from a pleural effusion. The MCF-12A and MDA-MB-231 cell 
lines were generously gifted to our department by Professor Sharon Prince at the 
University of Cape Town, while the BT-549 cell line was kindly donated by Professor 
Adrienne Edkins from Rhodes University. 
 
2.2.2 Maintenance conditions 
The MCF-12A cells were cultured in a 1:1 ratio of Dulbecco’s Modified Eagle’s Medium 
(DMEM; #41965-039, ThermoFisher) and Ham’s F12 Nutrient Mixture (Ham’s F12; 
#21765-029, ThermoFisher), supplemented with 0.01 mg/ml insulin (#783811004, 
Humulin 30/70, Lilly), 20 ng/ml human epidermal growth factor (EGF; #236-GMP, R&D 
Systems), 100 ng/ml Cholera toxin (#C8052, Sigma-Aldrich) and 500 ng/ml 




hydrocortisone (#H9611, LKT Laboratories). The BT-549 cells were cultured in 
Roswell Park Memorial Institute media (RPMI; #52400-025, ThermoFisher), 
supplemented with 0.01 mg/ml of insulin. The MDA-MB-231 cells were cultured in 
DMEM.  
All three cell lines were cultured in complete media, consisting of the aforementioned 
media and supplements, with the addition of 10% foetal bovine serum (FBS; #FBS-
GI-12A, Capricorn Scientific) and 1% Penicillin-Streptomycin (PenStrep; #15140-122, 
ThermoFisher). This was in line with the specifications issued by the leading global 
bioresource centre (ATCC, 2020). 
All cell lines were maintained in incubators at 37°C, a relative humidity of 95%, 21% 
oxygen and 5% carbon dioxide. Cells were cultured in T75 flasks until they reached a 
confluence of approximately 70-80%, whereafter they were passaged using 0.25% 
trypsin-EDTA (#25200-072, ThermoFisher) and seeded in new flasks, or in the 
appropriate plate for experimental purposes. 
 
2.2.3 Treatment conditions 
In order to mimic starvation in vitro, cells were cultured in low-glucose media (which 
contained approximately 70% less glucose than standard media), with reduced FBS 
(1% as opposed to 10%) for the duration of the starvation period. This is in line with 
previous studies (Raffaghello, et al., 2008; Lee, et al., 2012; Safdie, et al., 2012; 
Bianchi, et al., 2015; D’Aronzo, et al., 2015).  
Since low-glucose Hams’ F12 media was not available, glucose-free DMEM (#11966-
025, ThermoFisher) was purchased and mixed with standard Ham’s F12 to yield a 
low-glucose DMEM/F12 solution. This was repeated with glucose-free and standard 
DMEM for the MDA-MB-231 cells, and glucose-free RPMI (#11879-020, 
ThermoFisher) and standard RPMI for the BT-549 cells. All other supplements were 
added as per usual to the media of each respective cell line. Cells were starved for 
either 3, 6, or 24 hours, while the control group was not starved, and received standard 
media only. Treatment with doxorubicin hydrochloride (#D5794, LKT Laboratories) 





2.2.4 Incubation with bafilomycin 
Where autophagic outcomes were assessed, cells were incubated in 400 nM 
Bafilomycin A1 (#B1793, Sigma-Aldrich) for one hour prior to imaging with fluorescent 
microscopy, or for four hours prior to the harvesting of cells for western blotting. 
Bafilomycin A1 is a macrolide antibiotic isolated from Streptomyces griseus that 
prevents the acidification of the lysosome, consequently inhibiting its fusion with 
autophagosomes. As this results in the accumulation of autophagosomes, short-term 
treatment with bafilomycin A1 enables the quantification of autophagic flux using 
various techniques. 
 
2.3 Experimental techniques 
 
2.3.1 Western blotting 
In order to examine the change in the expression of specific target proteins, western 
blotting was performed following experimental treatments. This provided insight into 
the cellular response to starvation at specific time points. 
2.3.1.1 Cell harvesting and protein extraction 
Cells were seeded in T25 flasks and treated according to their experimental group. 
After the completion of the treatment period, culture medium was removed, and cells 
were washed three times with ice-cold PBS (See Appendix A) to remove traces of 
culture media. Thereafter, cells were harvested, while working on ice to minimise 
protein degradation, by using a cell scraper and a modified radio-immunoprecipitation 
(RIPA) buffer (1% NP-40, 1% Na-deoxycholate, 5 mM EDTA, 5 mM EGTA, 0.1% SDS) 
supplemented with cOmplete™ Protease Inhibitor Cocktail (#11697498001, Roche), 
1 mM Na3VO4, 1 mM NaF, and 1 mM PMSF. 
After the cells from each treatment group had been harvested and transferred to ice-
cold Eppendorf tubes, cells were sonicated (Misonix Sonicator, S-4000-010, QSonica) 
for five seconds at five amplitude and incubated on ice in a refrigerator until the foam 




of insoluble cellular debris from the supernatant. The latter was then collected to serve 
as the protein sample. 
2.3.1.2 Protein determination and the Bradford Assay 
The protein concentration of each sample was determined through the use of a 
Bradford colorimetric assay (Bradford, 1976). Using a bovine serum albumin (BSA) 
stock solution to generate a standard curve, absorbance values were read at 595 nm 
using a CE2021 Spectrophotometer (Cecil Instrumentation Services Ltd., Lasec). The 
protein concentration of each sample was established using the Bradford standard 
curve and this was used to calculate the volumes required to yield 50 µg of protein. 
Hereafter, the appropriate volume of protein sample was added to the relevant volume 
of sample buffer, boiled, vortexed and prepared for loading. 
2.3.1.3 SDS-PAGE and electro-transfer 
Protein samples were separated using sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE; Mini Protean System, Biorad) with self-cast gels and 
Tris/Glycine/SDS Running Buffer (#1610772, BioRad). Based on the size of the 
proteins being detected, either 12% or 15% gels were used. Equal amounts of protein 
(50 µg) were loaded into each lane, along with a protein marker ladder in the first lane. 
This molecular marker served as a guideline to locate each protein on the gel 
according to its molecular weight.  
Following electrophoresis, the separated proteins were activated on the Bio-Rad 
ChemiDoc MP, and transferred to a polyvinylidene fluoride (PVDF) membrane using 
the Trans-Blot Turbo RTA Transfer Kit, LF PVDF (#1704275, BioRad). A mixed 
molecular weight transfer was selected due to the broad range of molecular weights 
of the target proteins. Hereafter, the membrane was labelled and rinsed in 100% 
methanol and washed in Tris-buffered saline Tween (TBS-T). 
2.3.1.4 Immunodetection 
After the washing step, the membrane underwent a blocking step in 5% milk or BSA 
for one hour to prevent non-specific binding, followed by another washing step in TBS-
T. Hereafter the membrane was incubated overnight in the relevant primary antibody 
at 4°C. The proteins of interest during the first part of the study included Atg5, p62 and 




This provided insight into the change in cellular behaviour over time when confronted 
with nutrient deprivation, and also illustrated the roles played by intracellular signalling 
molecules in the adaptation of the cell to nutrient stress.  
After overnight incubation in the primary antibody, the membranes were washed in 
TBS-T and incubated for one hour in the appropriate secondary antibody. After a final 
washing step in TBS-T, a thin layer of Clarity™ Western ECL Substrate (#170-5061, 
BioRad) was evenly distributed over the membrane and an appropriate exposure 
setting was selected, in order to visualise the protein bands on a Bio-Rad ChemiDoc 
MP. Exposed bands were quantified using Image Lab v6.1 (BioRad). To account for 
variations in protein loading, these bands were normalised against the total protein 
within its respective lane. The relative target protein expression was quantified using 
densitometry software (Quantity One 1-D Analysis Software, BioRad) and presented 
as a percentage of the control. 
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1:1000 Anti-mouse (#7076S, CST), 1:10 000 85kDa 12% 
Akt Rabbit anti-Akt 
#ab32505 
Abcam 
















1:1000 Anti-rabbit (#7074S, CST) 1:10 000 55kDa 15% 
p62 Rabbit anti-p62 
#ab109012 
Abcam 







1:1000 Anti-rabbit (#7074S, CST) 1:10 000 14-16kDa 15% 






For the first part of the study, immunocytochemistry was used to determine the effect 
of different periods of starvation on the autophagic flux of three different cell lines. 
Immunocytochemistry is a technique whereby specific proteins and/or organelles are 
visualised using fluorescent probes and a specialised fluorescent microscope, with the 
goal of gaining insight into intracellular processes. Autophagic flux refers to the rate of 
protein degradation through autophagic pathways (Mizushima & Komatsu, 2011). In 
order to quantify autophagic flux within a cell, both the number of autophagosomes 
and lysosomes must be established, as well as the co-localisation thereof, thus 
indicating autolysosomes. Autophagosomes may be visualised in a number of ways, 
but this study employed the transfection of cells with a plasmid, namely eGFP-LC3 
(#21073, Addgene). LC3 is a protein found in the membranes of autophagosomes and 
the visualisation thereof using a fluorescent microscope is used to determine of the 
number of these autophagic vesicles within a cell. Similarly, LysoTracker™ Red DND-
99 (#L7528, ThermoFisher) is a fluorescent probe that labels lysosomes, enabling the 
visualisation of these organelles. By staining cells transfected with eGFP-LC3 with 
LysoTracker Red, both autophagosomes and lysosomes may be visualised, 
respectively. The formation of autolysosomes is thus observed by the co-localization 
of the green and red fluorescent signals. 
Each cell line was seeded and cultured in a T25 flask until a confluence of 
approximately 60-70% was attained. The Lipofectamine™ 3000 Transfection Reagent 
(#L3000-001, ThermoFisher) was used to transfect the cells with the eGFP-LC3 
plasmid. The eGFP-LC3 plasmid was originally donated by Tamotsu Yoshimori, and 
obtained from Addgene (Addgene plasmid #21073; http://n2t.net/addgene:21073; 
RRID:Addgene_21073).  
Thereafter, successfully transfected cells were selected by the addition of G418 
disulfate salt (A1720-1G, Sigma-Aldrich), an aminoglycoside antibiotic that kills non-
transfected cells. The continual selection of successfully transfected cells ensured a 
population suitable for fluorescent microscopy. These cells were then seeded in an 8-
well chamber slide and each experimental group was treated accordingly. LysoTracker 
Red, at a concentration of 80 nM, was added to each well three hours prior to imaging 




A 488 nm laser was used for the imaging of eGFP, which has excitation and emission 
wavelengths of 488/510 nm. A 561 nm laser was used for the visualisation of 
LysoTracker Red (577/590 nm). Triplicate images in the form of z-stacks, visualising 
one cell per image, were obtained per group. The experiment was repeated in 
triplicate, yielding a total of nine cells imaged per group. The images were processed 
using the Zeiss ZEN 3.2 Blue Edition software. Data were presented as the mean 
number of autophagosomes per cell. 
For a comprehensive protocol, please see Appendix B. 
 
2.3.3 Cell cycle analysis 
For the first part of the study, cell cycle analysis was performed using flow cytometry 
to establish the effect of starvation on the cell cycle in both malignant and normal cell 
lines. For the second part, the effect of starvation on chemosensitivity was determined 
by establishing whether cells that were starved prior to receiving doxorubicin displayed 
a greater extent of growth arrest. 
By permeabilising the cell membrane with 70% ethanol prior to the addition of a 
fluorescent dye (such as propidium iodide), the dye may permeate the cell membrane 
and stain all nucleic acids within the cell. However, with the addition of ribonuclease 
(RNase), propidium iodide stains only cellular DNA. The intensity of the fluorescent 
signal is thus directly proportional to the amount of DNA within the cell, which enables 
the flow cytometer to determine which stage of the cell cycle the cell is in. Cells in the 
G2/M phase have twice the amount of DNA as those in G0/G1, with everything in 
between falling within the S-phase category. This determination of cell cycle was 
achieved by using the BD FACSMelody to perform flow cytometry. 
For the analysis of the cell cycle, cells were seeded in T25 flasks at an appropriate 
density and given their respective treatments. At the end of the treatment period, cells 
were harvested, permeabilised with ethanol, resuspended in a solution of 
Ribonuclease A from bovine pancreas (#R4642-10mg, Sigma-Aldrich) and propidium 
iodide (PI; #P4170-10mg, Sigma-Aldrich) in phosphate buffered saline (PBS), and 
analysed using the BD FACSMelody cell sorter. By utilising the BD FlowJo™ v10.6 




parameters were set, and the data were extracted. Data were presented as the 
percentage of cells within each phase of the cell cycle. 
For a comprehensive protocol, please see Appendix B. 
 
2.3.4 Cell viability assay 
In order to determine the effect of starvation on cell viability over time, as well as the 
effect of starvation on chemosensitivity, a cell viability assay was conducted using a 
water-soluble tetrazolium salt 1 (WST1; #05015944001, Roche). 
WST1 is often employed to quantify the effects of a given treatment on cytotoxicity 
and cell proliferation. A WST1 assay is a colorimetric assay, as the tetrazolium salt is 
cleaved in the presence of viable cells to form yellow formazan. This reduction reaction 
relies predominantly of the production of NAD(P)H, which only occurs in metabolically 
active cells. The amount of formazan is therefore directly proportional to the level of 
activity of mitochondrial dehydrogenases, which generally corresponds with the 
number of live cells, and is thus used as a proxy for cell viability.  
Once cells had reached a confluence of 70-80%, cells were trypsinised and seeded at 
an appropriate density in 48-well plates. For the first part of the study, a viability assay 
was performed utilising a control group, and three starvation groups of varying 
durations (3, 6 and 24 hours). For the second part of the study, the groups comprised 
of a control group, a doxorubicin treatment group, a 24-hour starvation group, and a 
combination group.  
Each group consisted of triplicate wells, and each experiment was performed three 
times to account for both technical and biological replicates, respectively. At the end 
of the treatment periods, 10 µl of WST1 reagent was added to each well containing 
200 µl of growth medium, and the plates were incubated for two hours at 37°C. The 
absorbance values were read at 450 nm using the EL800 Universal Microplate Reader 
(Bio-Tek Instruments, Inc.). Cell viability was calculated and expressed as a 
percentage of the control values. 





2.3.5 Live cell count with trypan blue 
In order to determine the effect of starvation, doxorubicin and the combination thereof 
on live cell number and proliferation, the number of live cells was determined through 
the use of a live cell count with trypan blue. Trypan blue is generally excluded from 
viable cells, due to its inability to permeate intact cell membranes. 
Cells were seeded in T25 flasks at an appropriate density and given their respective 
treatments. At the end of the treatment period, growth medium was removed and 
discarded. Adherent cells were harvested using 0.25% trypsin-EDTA, neutralised with 
growth medium, and the T25 flasks rinsed with PBS to collect any remaining cells. The 
tube, containing PBS and cells in a trypsin suspension, was centrifuged for five 
minutes at 1500 rpm. The supernatant was discarded, and the cell pellet resuspended 
in 1000 µl warm PBS. In a labelled Eppendorf tube, 100 µl of this cell suspension was 
added to 100 µl of 0.1% trypan blue solution. This was prepared in advance from 
trypan blue and PBS. A volume of 10 µl from this suspension was loaded onto the 
grids of three Neubauer counting chambers and the number of viable (unstained) cells 
were counted. This was repeated in triplicate for each group, with the experiment also 
repeated in triplicate, thus accounting for technical and biological replicates. Data were 
presented as a percentage of the control. 
For a comprehensive protocol, please see Appendix B. 
 
2.3.6 Flow cytometry with propidium iodide 
For the second part of the study, cell viability was determined by using flow cytometry 
and propidium iodide. Notably, this did not involve a permeabilization step, as 
propidium iodide is intended to penetrate permeable, and therefore, non-viable cells, 
only. This determined the percentage of non-viable cells within the population.  
For the determination of cell viability, cells were seeded in T25 flasks at an appropriate 
density and given their respective treatments. At the end of the treatment period, cells 
were harvested, centrifuged, resuspended in a solution of propidium iodide in PBS 
and analysed using the BD FACSMelody cell sorter. By utilising the BD FlowJo™ 




parameters were set, and the data were extracted. Data are presented as the 
percentage of non-viable cells. 
 
2.4 Statistical analysis 
All data were captured and analysed using Statistica Version 13.6. Data are expressed 
as the mean ± standard error of the mean (SEM). Data were assessed for normality 
using the Kolmogorov-Smirnov test, and the following tests were used to establish 
significance: one-way ANOVA, Kruskal-Wallis test, Pearson’s correlation matrix. Data 





Chapter 3: Results 
 
Part 1: Cellular characterization of starvation 
 
3.1  The cellular response to starvation over time 
A normal breast epithelial cell line, MCF-12A, was selected as a control to determine 
the effects of starvation on benign cell behaviour. Two triple negative breast cancer 
(TNBC) cell lines, BT-549 and MD-MB-231, were selected to represent cancers with 
limited available therapeutic interventions. For the first part of the study, cells were 
seeded in the appropriate plates or flasks and treated according to their respective 
treatment group. Where autophagic outcomes were not assessed, four experimental 
groups were involved: 1) the control group, which received standard, fully 
supplemented media (Con); 2) a three-hour starvation period (3h); 3) a six-hour 
starvation period (6h); and 4) a 24-hour starvation period (24h). For experiments 
assessing autophagic outcomes, additional groups corresponding to those listed 
above, but supplemented with bafilomycin, were included, resulting in eight 
experimental groups. 
 
3.1.1 Metabolic signalling pathways in starvation 
In order to determine the effect of starvation on signalling pathways involved in growth 
and proliferation, western blotting was employed to quantify relative target protein 
expression. Membranes were visualised using the Image Lab™ software from Bio-
Rad™. Protein expression was normalised according to the total protein and 
expressed as a percentage of the control. 
 
3.1.1.1 The effect of starvation on Phosphatidylinositol 3-Kinase (PI3K)  
PI3K is a lipid kinase and oncoprotein that forms part of the PI3K/Akt/mTOR signalling 
pathway. This pathway is activated through receptor binding of multiple growth signals 




Restuccia, 2012). There were no significant differences in any of the groups in any of 
the cell lines. While the expression of PI3K increased with starvation in the MDA-MB-
231 cell line, none of the groups reached significance. Only the 24-hour starvation 
group approached significance (p=0.1).  
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Figure 3.1: The effect of starvation over time on PI3K expression. PI3K expression, as determined 
by western blotting, in MCF-12A cells, BT-549 cells and MDA-MB-231 cells. Results are presented as 
a percentage of the control ± SEM (n=3). * = p<0.05 when compared to the control. 
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3.1.1.2 The effect of starvation on total Akt expression 
Akt, also known as protein kinase B (PKB), is a serine/threonine kinase that is a 
downstream target of PI3K. Akt promotes cell survival, growth and proliferation 
(Cantley, 2002).  
In the MCF-12A cell line, the three-hour starvation group had significantly lower Akt 
expression than the control group (p<0.01). The 24-hour group approached but did 
not reach significance (p=0.08). There were no significant differences between any of 
the groups in the BT-549 cells. In the MDA-MB-231 cell line, there was a significant 
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Figure 3.2: The effect of starvation over time on Akt expression. Akt expression, as determined by 
western blotting, in MCF-12A cells, BT-549 cells and MDA-MB-231 cells. Results are presented as a 
percentage of the control ± SEM (n=3). * = p<0.05 when compared to the control.  
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3.1.1.3 The effect of starvation on Akt phosphorylation 
For Akt to be activated, it must be phosphorylated, both on Thr308 and at Ser473. The 
latter is executed by either mTOR or DNA-dependent protein kinases, and this 
stimulates full Akt activity (Hemmings & Restuccia, 2012).  
There were no significant differences between any of the groups in the MCF-12A cells. 
Only the three-hour group neared significance (p=0.1). There were also no significant 







            p-Akt                  60 kDa 
 






Figure 3.3: The effect of starvation over time on phosphorylated Akt (Ser473). Phosphorylated 
Akt, as determined by western blotting, in MCF-12A cells, BT-549 cells and MDA-MB-231 cells. Results 
are presented as a percentage of the control ± SEM (n=3). * = p<0.05 when compared to the control.  
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3.1.2 Autophagic flux in starvation 
In order to determine the effect of starvation on autophagy, Western blotting was 
employed to quantify the expression of Atg5, p62 and LC3-II. Immunocytochemistry 
was used to quantify autophagic puncta. 
3.1.2.1 The effect of starvation on Autophagy-related protein 5 (Atg5) 
expression 
Autophagy-related proteins (ATG) are key players in the autophagy pathway. 
ATG5 serves as a key factor and an integral part of the ATG5-ATG12-ATG16L1 
complex that catalyses the ATG8 lipidation essential for autophagosome formation 
and expansion. ATG5 is also indispensable for the fusion of autophagosomes with 
lysosomes in both canonical and noncanonical autophagy (Glick, et al., 2010). In the 
MCF-12A cell line, there was a near-significant difference in Atg5 expression between 
the control group and the 24-hour group (p=0.052). There were no significant 
differences between any of the groups in the BT-549 cells. In the MDA-MB-231 cell 
line, there were significant differences in the control (p<0.05), three-hour (p<0.05), six-
hour (p<0.01) and 24-hour (p<0.01) groups when compared to their corresponding 
bafilomycin-treated groups.  
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Figure 3.4: The effect of starvation over time on Atg5 expression. Atg5 expression, as determined 
by western blotting, in MCF-12A cells, BT-549 cells and MDA-MB-231 cells. Results are presented as 
a percentage of the control ± SEM (n=3). * = p<0.05 when compared to the control; # = p<0.05 when 
the group treated with bafilomycin is compared to the corresponding untreated time point.  
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3.1.2.2 The effect of starvation on p62 expression 
p62, also known as Sequestosome 1 (SQSTM1) is a protein that is required for 
selective macroautophagy. It is commonly used as a marker for autophagic 
degradation, displaying an inverse relationship with levels of autophagy and LC3-II, 
unless bafilomycin treatment induces its accumulation (Mizushima & Komatsu, 2011). 
There was a significantly greater expression of p62 in the respective bafilomycin-
treated groups than in the control (p<0.01), three-hour (p<0.001), six-hour (p<0.001) 
and 24-hour (p<0.01) groups in the MCF-12A cell line. In the BT-549 cells, there were 
no significant differences between groups. There was a significantly greater 
expression of p62 in the respective bafilomycin groups than the the six-hour group 
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Figure 3.5: The effect of starvation over time on p62 expression. p62 expression, as determined 
by western blotting, in MCF-12A cells, BT-549 cells and MDA-MB-231 cells. Results are presented as 
a percentage of the control ± SEM (n=3). * = p<0.05 when compared to the control; # = p<0.05 when 
the group treated with bafilomycin is compared to the corresponding untreated time point.  
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3.1.2.3 The effect of starvation on LC3-II expression 
LC3-I is converted to LC3-II during the maturation of autophagosomes. Quantifying 
the relative expression of LC3-II serves as an indicator of autophagic flux when 
combined with bafilomycin treatment (Mizushima & Komatsu, 2011). 
Treatment with bafilomycin significantly increased levels of LC3-II in the control, three-
hour, six-hour and 24-hour groups (p<0.0001) in the MCF-12A cells. The BT-549 cells, 
however, showed no significant differences when treated with bafilomycin. The MDA-
MB-231 cells only showed a significant increase in LC3-II with bafilomycin treatment 
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Figure 3.6: The effect of starvation over time on LC3-II expression. LC3-II expression, as 
determined by western blotting, in MCF-12A cells, BT-549 cells and MDA-MB-231 cells. Results are 
presented as a percentage of the control ± SEM (n=3). * = p<0.05 when compared to the control; # = 
p<0.05 when the group treated with bafilomycin is compared to the corresponding untreated time point.  
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3.1.2.4 The effect of starvation on the number of autophagosomes 
Another means of quantifying autophagy is by determining the average number of 
autophagosomes per cell. Cells were transfected with an eGFP-LC3 plasmid and 
stained with LysoTracker Red™. After z-stack images were obtained using the Carl 
Zeiss LSM 780 confocal microscope, individual puncta representing autophagosomes 
were counted. Data is presented as a percentage of the control.  
Bafilomycin treatment increased the number of autophagosomes in the control 
(p<0.001), six-hour (p<0.001), and 24-hour (p<0.0001) groups of the MCF-12A cells. 
In the BT-549 cells, bafilomycin increased the number of autophagosomes in the 
control (p<0.0001), three-hour (p<0.001), and six-hour (p<0.0001) group. Additionally, 
there was a significant difference between the control and three-hour group (p<0.05). 
In the MDA-MB-231 cell line, there was a significant increase in the three-hour 
(p<0.01), six-hour (p<0.0001) and 24-hour (p<0.0001) group when compared to the 
control group. Additionally, the control, three-hour and six-hour groups had a 















Figure 3.7: The effect of starvation over time on the number of autophagosomes. The number of 
autophagosomes, as determined by fluorescent microscopy, in MCF-12A cells, BT-549 cells and MDA-
MB-231 cells. Results are presented as the mean number of puncta per cell ± SEM (n=3). * = p<0.05 
when compared to the control; # = p<0.05 when the group treated with bafilomycin is compared to the 














3.1.2.5 Representative images for LC3 puncta quantification 
a) Con b) Con + Baf 
c) 3h d) 3h + Baf 





Figure 3.8: Representative images for visualisation of autophagosomes and lysosomes in MCF-
12A cells following different periods of starvation. eGFP-LC3 transfected MCF-12A cells were 
seeded and starved for 3-, 6- and 24-hours, and stained with LysoTracker Red. Bafilomycin was added 
at a concentration of 400 nM one hour prior to imaging on the Carl Zeiss LSM 780 confocal microscope. 
The scale bar represents 20 µm. 





a) Con b) Con + Baf 
c) 3h d) 3h + Baf 
e) 6h 





Figure 3.9: Representative images for visualisation of autophagosomes and lysosomes in BT-
549 cells following different periods of starvation. eGFP-LC3 transfected BT-549 cells were seeded 
and starved for 3-, 6- and 24-hours, and stained with LysoTracker Red. Bafilomycin was added at a 
concentration of 400 nM one hour prior to imaging on the Carl Zeiss LSM 780 confocal microscope. 
The scale bar represents 20 µm. 
  





a) Con b) Con + Baf 
c) 3h d) 3h + Baf 
e) 6h 





Figure 3.10: Representative images for visualisation of autophagosomes and lysosomes in 
MDA-MB-231 cells following different periods of starvation. eGFP-LC3 transfected MDA-MB-231 
cells were seeded and starved for 3-, 6- and 24-hours, and stained with LysoTracker Red. Bafilomycin 
was added at a concentration of 400 nM one hour prior to imaging on the Carl Zeiss LSM 780 confocal 
microscope. The scale bar represents 20 µm. 
 
  




3.1.3 The effect of starvation on cell cycle progression 
To establish the effect of starvation over time on cell cycle progression and growth 
arrest, cell cycle analysis was performed.  
In the MCF-12A cell line, the proportion of cells in the G0/G1 phase increased with 
starvation, with significantly higher percentages in the six-hour (p<0.05) and 24-hour 
(p<0.01) groups. All three starvation periods reduced the proportion of cells in the S-
phase (p<0.05). There were no significant differences between any of the groups in 
the percentage of cells in the G2/M phase. 
 
Figure 3.11: The effect of starvation over time on cell cycle progression in MCF-12A cells. The 
percentage of cells in the G0/G1 phase, S phase and G2/M phase, as determined by flow cytometry, in 
MCF-12A cells. Results are presented as the mean percentage of cells per group ± SEM (n=3). * = 
p<0.05 when compared to the control.  







Only a starvation period of 24-hours significantly increased the percentage of cells in 
the G0/G1 phase (p<0.0001) in the BT-549 cells when compared to the control. There 
were significantly fewer cells in the S phase in the six-hour (p<0.05) and 24-hour 
(p<0.0001) groups. The three-hour (p<0.001), six-hour (p<0.001) and 24-hour 




Figure 3.12: The effect of starvation over time on cell cycle progression in BT-549 cells. The 
percentage of cells in the G0/G1 phase, S phase and G2/M phase, as determined by flow cytometry, in 
BT-549 cells. Results are presented as the mean percentage of cells per group ± SEM (n=3). * = p<0.05 
when compared to the control. 
 
  








In the MDA-MB-231 cell line, there were significantly more cells in the G0/G1 phase in 
the six-hour and 24-hour groups (p<0.05). Starvation significantly reduced the 
proportion of cells in the S phase in the six-hour and 24-hour groups (p<0.01). Only 
the three-hour group displayed a significant increase in the percentage of cells in the 
G2/M phase (p<0.05). 
 
 
Figure 3.13: The effect of starvation over time on cell cycle progression in MDA-MB-231 cells. 
The percentage of cells in the G0/G1 phase, S phase and G2/M phase, as determined by flow cytometry, 
in MDA-MB-231 cells. Results are presented as the mean percentage of cells per group ± SEM (n=3). 
* = p<0.05 when compared to the control. 
  









3.1.4 The effect of starvation on cell viability 
In order to determine the effect of starvation over time on cell viability, a WST1 assay 
was conducted. WST1 is reduced to formazan through the production of NAD(P)H, 
which only occurs in metabolically active cells. The level of mitochondrial activity 
therefore determines the amount of formazan produced. This generally corresponds 
with the number of live cells and is thus used as a proxy for cell viability (Van den 
Berghe, et al., 2013). There was a small but significant increase in cell viability in the 
three-hour (p<0.01) and six-hour (p<0.001) starvation groups in the MCF-12A cells, 
but not in the 24-hour group. In the BT-549 cell line, there was a significant reduction 
in cell viability following three and six hours of starvation (p<0.0001). Compared to the 
control group, the three-hour (p<0.001) and six-hour (p<0.01) groups displayed 
significantly higher viability in the MDA-MB-231 cells, while 24 hours of starvation 
resulted in a small but significant reduction in cell viability (p<0.05). 
 
Figure 3.14: The effect of starvation over time on cell viability. Cell viability, as determined by WST1 
assay, in MCF-12A cells, BT-549 cells and MDA-MB-231 cells. Results are presented as the mean 








3.1.5 Selection of a starvation period 
Based on the above data, a starvation period of 24 hours was selected for the 
remainder of the study. By 24 hours, the difference from the control group was often 
the most notable but did not significantly reduce cell viability. Additionally, this period 
of starvation was commonly used in the literature (Raffaghello, et al., 2008; Safdie, et 
al., 2012; D’Aronzo, et al., 2015). Lastly, this time point reflects ex vivo conditions most 




Part 2: The effect of starvation on chemosensitivity 
 
3.2.1  Doxorubicin dose-response viability study 
A dose-response viability study was first conducted to select an appropriate 
concentration for treatment with doxorubicin. A WST1 assay was used to establish the 
effect of different concentrations on cell viability. In the MCF-12A cell line, all five 
concentrations of doxorubicin were able to significantly reduce cell viability (p<0.001). 
However, this effect became more pronounced with concentrations higher than 5 µM. 
The BT-549 cell line only showed a significant reduction at 2.5 µM (p<0.001), and for 
both concentrations thereafter. The MDA-MB-231 cells showed a small but significant 
reduction in cell viability from 2.5-10 µM (p<0.01). Based on these results, a 
concentration of 2.5 µM was selected to serve as the concentration for doxorubicin 
treatment for the remainder of this study. This concentration significantly reduced cell 
viability by approximately 17% in the MCF-12A cells, 15% in the BT-549 cells and 9% 
in the MDA-MB-231 cells. This was considered sufficient to illustrate either enhanced 







Figure 3.15: Doxorubicin dose-response viability studies. Cell viability, as determined by a WST1 
assay, in MCF-12A cells, BT-549 cells and MDA-MB-231 cells. Results are presented as a percentage 
of the control ± SEM (n=3). * = p<0.05 when compared to the control.  
 
3.2.2  Treatment conditions 
For the second part of the study, cells were seeded in plates or flasks and treated 
according to their respective treatment group. A total of four experimental groups were 
included: 1) a control group (Con); 2) a 24-hour starvation period (St); 3) a 24-hour 
treatment period with doxorubicin (Dox); 4) a 24-hour starvation period followed by a 
24-hour treatment period with doxorubicin (StDox).  
Cells were starved using low-glucose media with reduced FBS (1% as opposed to 
10%). Doxorubicin treatment was administered at a concentration of 2.5 µM in 
standard media. All cells not receiving treatment were refreshed with fully 
supplemented standard media. 
All data were assessed for normality using the Kruskal-Wallis test. Data were analysed 
using one-way ANOVAs. In terms of statistical significance, * = p<0.05 when 







3.2.3 The effect of starvation and doxorubicin on live cell number 
A live cell count was employed to establish the effects of starvation, doxorubicin and 
the combination thereof on the total number of viable cells. Cells undergoing stress 
may respond in a variety of ways which, among others, may include either a reduction 
in their rate of proliferation, or the induction of cell death. Both of these mechanisms 
would result in a lower live cell count, and it was later established through viability 
studies and cell cycle analysis which accounted for the changes in cell number.  
In the MCF-12A cell line, both the doxorubicin (p<0.001) and combination treatment 
(p<0.001) significantly reduced the number of live cells when compared to the control. 
There was no significant difference between the doxorubicin and combination groups. 
This trend was also observed in the BT-549 cell line, with significantly fewer live cells 
in both the doxorubicin treatment group (p<0.001) and the combination group 
(p<0.01). While there were a greater number of live cells in the combination group than 
the doxorubicin treatment group, this did not achieve statistical significance (p=0.155). 
In the MDA-MB-231 cells, there was a significant reduction in live cell number between 
the control group and the doxorubicin treatment group (p<0.05), as well as the 
combination group (p<0.01). While there were fewer cells in the combination group 









Figure 3.16: The effect of starvation, doxorubicin and the combination thereof on live cell 
counts. Total number of live cells, as determined by a cell count with trypan blue, in MCF-12A cells, 
BT-549 cells and MDA-MB-231 cells. Results are presented as a percentage of the control ± SEM (n 










3.2.4 The effect of starvation and doxorubicin treatment on cell viability 
using flow cytometry with a propidium iodide stain 
To further examine the effect of starvation on chemosensitivity, cell viability was 
assessed through the use of flow cytometry with propidium iodide. Propidium iodide is 
generally excluded from viable cells due to its inability to permeate intact cell 
membranes. When cells become non-viable, membrane integrity is lost. This allows 
the dye to enter the cell and bind to nucleic acids, serving as a marker for non-viable 
cells. 
In both the MCF-12A and MDA-MB-231 cell lines, there were no significant differences 
in the percentage of dead cells between any of the groups. However, in the BT-549 
cells, there was a small, but significant difference between the combination group and 
both the control group (p<0.001), and the doxorubicin group (p<0.01). 
Figure 3.17: The effect of starvation, doxorubicin, and the combination thereof on cell death. 
Percentage of dead cells, determined using flow cytometry with propidium iodide, in MCF-12A cells, 
BT-549 cells and MDA-MB-231 cells. Results are presented as the mean percentage of non-viable cells 
per group ± SEM (n=3). * = p<0.05 when compared to the control; # = p<0.05 when compared to the 







3.2.5 The effect of starvation and doxorubicin treatment on cell viability 
In order to determine the effect of starvation on chemosensitivity, a WST1 assay was 
conducted. There was a small but significant reduction in cell viability following 
starvation in the MCF-12A cell line (p<0.05). However, there was a greater reduction 
in viability following the doxorubicin (p<0.0001) and combination (p<0.0001) 
treatments. There was also a small but significant difference between the doxorubicin 
and combination groups (p<0.01). In the BT-549 cell line, there was a small but 
significant reduction in cell viability when comparing the control group to the starvation 
(p<0.01), doxorubicin (p<0.05) and combination groups (p<0.0001). There was also a 
significant difference between the doxorubicin and combination group (p<0.05). In the 
MDA-MB-231 cells, a small but significant reduction in cell viability followed starvation 
(p<0.01), doxorubicin (p<0.01) and the combination treatments (p<0.0001). There was 
also a significant difference between the doxorubicin and combination group (p<0.05). 
 
 
Figure 3.18: The effect of starvation, doxorubicin, and the combination thereof on cell viability. 
Cell viability, as determined by WST1 assay in MCF-12A cells, BT-549 cells, and MDA-MB-231 cells. 
Results are presented as the mean percentage of viable cells per group ± SEM (n=3). * = p<0.05 when 









3.2.6 The effect of starvation and doxorubicin treatment on cell cycle 
progression 
To establish the effect of starvation on chemosensitivity in terms of cell cycle 
progression and growth arrest, cell cycle analysis was performed. This involves the 
permeabilization of the cell membrane and the addition of a fluorescent dye (such as 
propidium iodide). When combined with ribonuclease, propidium iodide stains only 
cellular DNA, with the intensity of the fluorescent signal reflecting the amount of DNA 
within the cell. This illustrates which stage of the cell cycle the cell is in. Cells in the 
G2/M phase have twice the amount of DNA as those in G0/G1, with everything between 
falling within the S-phase category. This determination of cell cycle was achieved by 
using the BD FACSMelody to perform flow cytometry.  
Compared to the control group in the MCF-12A cell line, there were significantly fewer 
cells in the G0/G1 phase in both the starvation group (p<0.05) and the doxorubicin 
treatment group (p<0.0001). There were, however, significantly more in the 
combination group than in the control (p<0.05), or in the group that received 
doxorubicin alone (p<0.0001). A significantly greater proportion of cells were found to 
be in the S phase in the doxorubicin group than in the control group (p<0.001) or the 
combination group (p<0.01). In terms of cells in the G2/M phase, when compared to 
the control group, both the starvation group and the doxorubicin treatment group 
approached but did not achieve significance (p=0.07). The combination group had 
significantly fewer cells in the G2/M phase than either the control group (p<0.01) or the 







Figure 3.19: The effect of starvation, doxorubicin, and the combination thereof on cell cycle 
progression in MCF-12A cells. The percentage of cells in the G0/G1 phase, S phase and G2/M phase, 
as determined by cell cycle analysis, in MCF-12A cells. Results are presented as the mean percentage 
of cells in each phase per group ± SEM (n=3). * = p<0.05 when compared to the control; # = p<0.05 











In the BT-549 cell line, there were significant differences in the proportion of cells in 
the G0/G1 phase between the control group and both the doxorubicin treatment group 
(p<0.001), and the combination group (p<0.001), but not between the doxorubicin 
treatment group and the combination group (p=0.4229). There were significantly more 
cells in the S phase in the doxorubicin treatment group than in both the control group 
(p<0.0001) or the combination group (p<0.01). There was also a significant difference 
between the control group and the combination group (p<0.001). In terms of the 
proportion of cells in the G2/M phase, there were no statistically significant differences 
between groups. Only the combination group achieved a near-significant difference 
when compared to the control group (p=0.065). 
 
 
Figure 3.20: The effect of starvation, doxorubicin, and the combination thereof on cell cycle 
progression in BT-549 cells. The percentage of cells in the G0/G1 phase, S phase and G2/M phase, 
as determined by cell cycle analysis, in BT-549 cells. Results are presented as the mean percentage 
of cells in each phase per group ± SEM (n=3). * = p<0.05 when compared to the control; # = p<0.05 









In the MDA-MB-231 cell line, there were small but significant differences in the 
proportion of cells in the G0/G1 phase between the control group and the starvation 
group (p<0.01), as well as the combination group (p<0.01). There were more 
pronounced differences when comparing the doxorubicin treatment group to both the 
control (p<0.0001), and combination treatment groups (p<0.0001). There were 
significantly more cells in the S phase in the doxorubicin treatment group than in the 
control group (p<0.001) or the combination group (p<0.05). There were also small but 
significant differences between the control group and both the starvation group 
(p<0.05), and the combination group (p<0.05). Lastly, the doxorubicin group had a 
significantly greater proportion of cells in the G2/M phase than either the control group 
(p<0.01) or the combination group (p<0.01). 
Figure 3.21: The effect of starvation, doxorubicin, and the combination thereof on cell cycle 
progression in MDA-MB-231 cells. The percentage of cells in the G0/G1 phase, S phase and G2/M 
phase, as determined by cell cycle analysis, in MDA-MB-231 cells. Results are presented as the mean 
percentage of cells in each phase per group ± SEM (n=3). * = p<0.05 when compared to the control; # 












Chapter 4: Discussion 
 
Breast cancer currently accounts for 25.4% of female cancer diagnoses globally. It is 
therefore the most common cancer among women in both developed and developing 
countries (WHO, 2018). Treatment resistance is an increasing challenge in the 
management of the disease, posing a threat to patient outcome and prognosis 
(Foulkes, et al., 2010). Of all the different types of breast cancer, TNBC is the most 
aggressive and has the worst prognosis as drug-resistance is common among this 
subtype (Foulkes, et al., 2010). As a result, extensive research is being conducted in 
order to find adjuvant therapies that may improve drug sensitivity.  
While there are many unique hallmarks of cancer that distinguish it from benign tissue, 
its high metabolic rate and excessive consumption of nutrients make it an ideal target 
for metabolic adjuvant therapies (Berger, 2014). We therefore set out to investigate 
the effect of STS on the growth, viability, and metabolism of TNBC cells and a benign 
breast epithelial cell line. We also investigated the effect of STS on chemosensitivity 
in these cells to see whether it offers any potential in the face of current treatment 
regimes. 
We hypothesised that STS prior to doxorubicin treatment would selectively enhance 
treatment efficacy in cancer cells, while offering protection to non-malignant cells. Our 
aims were as follows: firstly, to explore the effect of starvation over time on intracellular 
signalling pathways, autophagic flux, cell cycle progression, and viability in BT-549 
and MDA-MB-231 breast cancer cells, as well as in MCF-12A breast epithelial cells; 
secondly, to determine the effects of starvation, doxorubicin treatment, and the 
combination thereof on live cell number, cell viability, and cell cycle progression to 
establish chemosensitivity. 
 
4.1  Part one: the cellular response to starvation over time 
The first part of the study investigated the effect of starvation over time on intracellular 





4.1.1 Starvation reduces growth and proliferation signalling in MCF-12A, but 
not in BT-549 or MDA-MB-231 cells 
In order to determine the effect of starvation on signalling pathways involved in growth 
and proliferation, western blot analyses were employed to quantify relative target 
protein expression. Two core proteins involved in the promotion of cell growth and 
proliferation were selected: PI3K and Akt, with phosphorylated Akt also quantified. 
PI3K is a lipid kinase that forms part of the PI3K/Akt/mTOR pathway (Hemmings & 
Restuccia, 2012). It is downstream of multiple growth signals and is upregulated to 
promote cellular survival, growth and proliferation. When phosphorylated, PI3K is 
activated and converts PIP2 to PIP3, thereby recruiting PDK1 and Akt to the cell 
membrane for phosphorylation and activation (Hemmings & Restuccia, 2012). Akt, 
also known as protein kinase B (PKB), is a serine/threonine kinase that is a 
downstream target of PI3K, as well as other growth-promoting pathways. When 
activated through phosphorylation, Akt has multiple downstream effects, such as the 
inhibition of autophagy, and the promotion of glycolysis, protein synthesis, cell survival 
and proliferation (Kuhajda, 2008).  
While it may seem that nutrient- and serum-deprivation would attenuate growth and 
proliferation pathways, this was the case in only the benign cell line. Although the 6- 
and 24-hour time points yielded no significant changes, the MCF-12A cells displayed 
a significant decrease in Akt expression after three hours of starvation (p<0.01) (Figure 
3.2). PI3K and phosphorylated Akt also appeared to diminish. However, the former 
was not significant (Figure 3.1), and the latter only approached significance (p<0.10) 
(Figure 3.3). These findings are similar to those obtained by Muranen, et al. (2017), 
who found that MCF-10A breast epithelial cells reduced phosphorylated Akt 
expression when cultured for 24 hours in media free from serum, insulin and EGF. 
While this model of starvation differs from ours in that we did not restrict insulin and 
EGF, but glucose instead, it represents the principle that benign cells may reduce Akt 
signalling when faced with serum and nutrient deprivation. 
Contrarily, the BT-549 cell line displayed no significant reduction in any of these growth 
signalling proteins at any of the starvation time points (Figure 3.1; Figure 3.2; Figure 
3.3). This is concurrent with the findings of Zhang, et al. (2017) who found no 




incubated in serum-free media overnight. These findings may, in part, be explained by 
a PTEN mutation in BT-549 cells (Torbett, et al., 2008). PTEN plays an essential role 
in the suppression of the PI3K/Akt pathway, and this loss of PTEN function may cause 
dysregulations in the cell’s response to starvation, thereby preventing the appropriate 
downregulation under conditions of nutrient deprivation (Torbett, et al., 2008). 
Interestingly, the MDA-MB-231 cells showed an increase in PI3K expression with 
increasing duration of starvation (Figure 3.1). However, this was not significant, and 
only the 24-hour group approached significance (p=0.1). This lack of significance may 
be partially due to variability in the data, and we recommend a higher number of 
replicates for future experiments to reduce variability. The MDA-MB-231 cells 
displayed a similar trend between PI3K and Akt expression, which increased as 
starvation duration increased (Figure 3.2). Variability in Akt expression was less, and 
the 6- and 24-hour time points displayed significantly higher Akt expression (p<0.05 
and p<0.01, respectively). However, this trend was not maintained when examining 
phosphorylated Akt, as none of the groups illustrated significant changes (Figure 3.3). 
In a study by Yi, et al. (2013), serum-starved MDA-MB-231 cells also showed no 
significant changes in the expression of phosphorylated Akt when compared to the 
control group. However, MDA-MB-436 and HCC-1937 cells showed significantly 
higher expressions of total Akt following serum starvation (Yi, et al., 2013). Both of 
these cell lines carry BRCA1 mutations, which are associated with hyperactivated 
PI3K/Akt pathways (Elstrodt, et al., 2006). While BT-549 and MDA-MB-231 cells do 
not carry this mutation, it has been reported that these cells contain an allelic loss at 
BRCA1 (Elstrodt, et al., 2006). In summary, these findings suggest that some breast 
cancer cell lines may either resist the downregulation of pro-growth pathways in 
response to starvation, or even upregulate them, and that this may be influenced by 





4.1.2 Starvation upregulates autophagy in MCF-12A and MDA-MB-231 cells, 
but not BT-549 cells 
Western blot analyses were utilised to assess changes in autophagy over time during 
starvation. Total Atg5, p62 and LC3-II expression were quantified. Thereafter, 
immunocytochemistry was employed to further examine autophagy. eGFP-LC3-
transfected cells were treated and stained with LysoTracker Red™, and images were 
obtained using a confocal microscope. The average number of autophagosomes per 
cell was calculated and presented by group.  
LC3-II is produced through the modification of LC3-I during the maturation of 
autophagosomes. It is therefore an indicator of the rate of autophagosome initiation 
(Mizushima & Komatsu, 2011). When cells are treated with bafilomycin, which impairs 
the fusion of autophagosomes with lysosomes, LC3-II accumulates and may serve as 
an indicator of autophagic flux (Gottlieb, et al., 2015). p62, also known as 
Sequestosome 1 (SQSTM1), is a protein that acts as a substrate during autophagic 
degradation (Mizushima & Komatsu, 2011). p62 displays an inverse relationship with 
LC3-II, unless autolysosomal fusion is inhibited. Under such circumstances, p62 will 
not undergo degradation, but accumulate within the cell (Gottlieb, et al., 2015). 
Besides LC3-II and p62, other autophagy-related proteins may be used to measure 
autophagy, such as Atg5. Quantifying these proteins provides support to findings from 
LC3-II and p62 determination. Atg5 is an intracellular protein that forms part of the 
Atg5-Atg16-Atg12 complex, which is essential for the elongation of the phagophore. It 
is upregulated when autophagic activity increases (Glick, et al., 2010).  
In the MCF-12A cell line, there were no significant differences in Atg5 expression 
between any of the group (Figure 3.4). However, there was a significantly greater 
expression of p62 in the respective bafilomycin-treated groups than in the control 
(p<0.01), three-hour (p<0.001), six-hour (p<0.001) and 24-hour (p<0.01) groups, with 
the largest difference at three hours. Levels of LC3-II in the control, three-hour, six-
hour and 24-hour groups all increased significantly with bafilomycin treatment 
(p<0.0001). Lastly, bafilomycin treatment increased the number of autophagosomes 
in the control (p<0.001), six-hour (p<0.001), and 24-hour (p<0.0001) groups in these 
cells. These findings are corroborated by those of Thomas, et al. (2020) who found 




in MCF-12A cells, and that this was increased with the addition of bafilomycin. This 
may indicate that autophagic flux is upregulated in benign cells in response to nutrient 
deprivation. 
There were no significant differences between any of the groups in the BT-549 cells 
in terms of Atg5, p62 or LC3-II expression (Figure 3.4; Figure 3.5; Figure 3.6). There 
are currently limited studies examining the effects of starvation on markers of 
autophagic flux in BT-549 cells. However, in response to other stressors, these cells 
have been reported to display a weaker upregulation of autophagic flux than MDA-
MB-231 cells. These stressors include doxorubicin (Zhu, et al., 2015) and a bacterial 
enterotoxin (Masso-Welch, et al., 2019). However, when utilising fluorescent 
microscopy, it was observed that the three-hour starvation group had a significantly 
higher number of autophagosomes per cell than the control group (p<0.05) (Figure 
3.7). Additionally, bafilomycin treatment increased the number of autophagosomes in 
the control (p<0.0001), three-hour (p<0.001), and six-hour (p<0.0001) group, 
indicating upregulated autophagic flux at these time points. Notably, very few puncta 
were observed per cell, which may suggest low baseline levels of autophagy in these 
cells. Therefore, more sensitive techniques, such as fluorescent microscopy, may be 
needed to detect changes in autophagic activity. 
In the MDA-MB-231 cell line, there were significant differences in Atg5 expression 
between the control (p<0.05), three-hour (p<0.05), six-hour (p<0.01) and 24-hour 
(p<0.01) groups and their corresponding bafilomycin-treated groups (Figure 3.4). 
There was also a significantly greater expression of p62 in the respective bafilomycin 
groups than the the six-hour group (p<0.05) as well as the 24-hour group (p<0.01) 
(Figure 3.5), suggesting increased autophagic flux at these time points. LC3-II 
expression, however, was only significantly increased at the 24-hour time point with 
bafilomycin treatment (p<0.001) (Figure 3.6). Zhu, et al. (2017) demonstrated that 
MDA-MB-231 cells increased the expression of both p62 and LC3-II when incubated 
in serum-free media for 24 hours and treated with bafilomycin. This supports the notion 
that autophagic flux is upregulated in these cells after 24 hours of starvation. Lastly, 
fluorescent microscopy illustrated a significant increase in the number of 
autophagosomes at the three-hour (p<0.01), six-hour (p<0.0001) and 24-hour 
(p<0.0001) group when compared to the control group (Figure 3.7), indicating high 




of Zhu, et al. (2017) who found that the number of autophagosomes per cell were 
significantly upregulated at 24 hours of incubation in serum-free media.  Additionally, 
the control, three-hour and six-hour groups had a significantly higher number of 
autophagosomes when treated with bafilomycin (p<0.0001). 
 
4.1.3 Starvation increases the proportion of cells in the G0/G1 phase in MCF-
12A, BT-549 and MDA-MB-231 cells 
To establish the effect of starvation over time on cell cycle progression and growth 
arrest, cell cycle analysis was performed using propidium iodide, ribonuclease, and 
the BD FACSMelody flow cytometer. 
In the MCF-12A cell line, the proportion of cells in the G0/G1 phase increased with the 
duration of starvation, with significantly higher percentages in the six-hour (p<0.05) 
and 24-hour (p<0.01) groups (Figure 3.11). This is commonly seen in cultured cells in 
response to serum-starvation, especially in those of benign origins (Felice, et al., 2009; 
Yao, 2014). There were no significant differences between any of the groups in the 
percentage of cells in the G2/M phase, but all three starvation periods significantly 
reduced the proportion of cells in the S-phase (p<0.05) (Figure 3.11). As data from cell 
cycle analysis are represented as percentages of the total number of cells, rather than 
crude values, an increase in one category would naturally result in a decrease in 
another. Thus, we suspect that the relative decrease in the proportion of cells in the 
S-phase is the result of the G0/G1 portion expanding, rather than an active upregulation 
of cells within the S-phase. 
In the MDA-MB-231 cell line, a similar trend was observed as in the MCF-12A cells, 
with significantly more cells in the G0/G1 phase of the six-hour and 24-hour groups 
(p<0.05) (Figure 3.13). This is concurrent with a study by Barascu, et al. (2006) as a 
24-hour period of serum starvation was used to induce G0/G1 arrest in these cells. 
While the model for starvation may differ, Thomas, et al. (2020) also illustrated a 
significant increase in the proportion of cells in the G0/G1 phase after 24 hours of amino 
acid starvation, but not at six or 12 hours. This may indicate that longer periods of 




In the BT-549 cells, a significant increase in the percentage of cells in the G0/G1 phase 
was only observed at 24-hours when compared to the control (p<0.0001) (Figure 
3.12). This significant change was only observed at a later stage than in the other cell 
lines. BT-549 cells are reported to have mutations in the PTEN, Rb and TP53 genes, 
all of which regulate the cell cycle (ATCC, 2020). Additionally, Furnari, et al. (1998) 
illustrated that the passage of serum-starved Glioma cells into G1 growth arrest was 
mediated by PTEN. If these mechanisms are similar in other types of cancer, the BT-
549 cells may have been able to resist G0 growth arrest for longer than the other cell 
lines, or otherwise were able to adapt to the shorter time points of starvation better 
than the other cell lines could. There were significantly fewer cells in the S phase in 
the six-hour (p<0.05) and 24-hour (p<0.0001) groups. The three-hour (p<0.001), six-
hour (p<0.001) and 24-hour (p<0.05) had a significantly higher percentage of cells in 
the G2/M phase than the control group (Figure 3.12). 
These results illustrate that cancer cells may also enter G0 (quiescence) or G1 growth 
arrest in sub-optimal nutrient availability, as benign cells do. However, the mutations 
in genes that regulate the cell cycle may influence the conditions under which these 
states are entered, and whether they are permanent or not. For future studies, it may 
be worth investigating whether conditions of starvation result in a permanent exit from 
the cell cycle by quantifying markers of senescence (p21, RB and p53). 
 
4.1.4 Starvation has varied effects when using bio-reductive capacity as an 
indicator of cell viability 
In order to determine the effect of starvation over time on cell viability, a WST1 assay 
was conducted. In the benign breast epithelial cell line, there was a small but 
significant increase in cell viability in the three-hour (p<0.01) and six-hour (p<0.001), 
but not in the 24-hour starvation group (Figure 3.14). This is in contrast with the 
findings of Govender (2013) who found that viability in MCF-12A cells was significantly 
decreased by both six and 24 hours of starvation. However, starvation was simulated 
using Hank’s Balanced Salt Solution (HBSS), in contrast to our low-glucose and 
reduced-serum media. HBSS represents a more severe state of nutrient deprivation, 
as it lacks most metabolites, and may thus explain the difference in findings. Thomas, 




of starvation was not sufficient to significantly reduce cell viability in MCF-12A cells. 
This supports our findings that MCF-12A cells are able to withstand less severe forms 
of nutrient deprivation over a 24-hour period. While it may be possible that STS 
promotes cell proliferation in some cell lines, none of the proliferative pathways were 
significantly upregulated in MCF-12A cells, which makes it unlikely that proliferation 
was responsible for the increase in viability. On the contrary, starvation significantly 
increased the proportion of cells within the G0/G1 phase at six and 24 hours. This is 
characteristic of benign cells in response to serum- and nutrient-deprivation, and 
potentially indicates a temporary state of quiescence in response to suboptimal 
nutrient availability. It is more likely that this reported increase in viability may reflect 
cellular activity rather than live cell number. WST1 is a tetrazolium salt that is reduced 
by the production of NAD(P)H at the respiratory chain of the mitochondria. While viable 
cells are metabolically active, the level of metabolic activity may change in response 
to certain stressors, especially in the context of nutrient deprivation where autophagy 
and other compensatory pathways may be upregulated. This may lead to 
overestimations of cell viability in assays which use metabolic activity as a proxy for 
cell viability (Van den Berghe, et al., 2013). A WST1 assay is therefore a direct 
indicator of bio-reductive capacity, and only an indirect measure of viability. In this 
case, the MCF-12A cells may have displayed increased cellular metabolism in the 
early stages of starvation, which was later reduced as the cell achieved homeostasis. 
In the BT-549 cell line, there was a significant reduction in cell viability following three 
and six hours of starvation (p<0.0001) (Figure 3.14), which may indicate reduced 
metabolic activity in response to starvation, rather than reduced viability (Van den 
Berghe, et al., 2013). These cells displayed a weaker upregulation of autophagy in 
response to starvation than the other cell lines. Thus, reduced, rather than increased, 
metabolic activity may follow starvation (Van den Berghe, et al., 2013).  
Compared to the control group, the three-hour (p<0.001) and six-hour (p<0.01) groups 
displayed significantly higher viability in the MDA-MB-231 cells, while 24 hours of 
starvation resulted in a small but significant reduction in cell viability (p<0.05) (Figure 
3.14). The former may again be the result of increased metabolic activity, while the 
latter may reflect the G0/G1 shift in response to starvation. Alternatively, these findings 
are similar to those of Thomas, et al. (2020) who demonstrated that total amino acid 




4.2 Part two: the effect of starvation on chemosensitivity  
The second part of the study investigated the effect of starvation on chemosensitivity. 
The outcomes included the total number of live cells, cell death, bio-reductive capacity 
as an indicator of viability, and cell cycle progression. 
 
4.2.1  Doxorubicin reduces cell viability in MCF-12A, BT-549 and MDA-MB-
231 cells  
A dose-response curve was conducted to select an appropriate concentration for 
doxorubicin treatment. A WST1 assay was used to establish the effect of different 
concentrations of doxorubicin on cell viability. 
A concentration of 2.5 µM was able to significantly reduce cell viability in the MCF-
12A, BT-549 and MDA-MB-231 cells (Figure 3.15). These findings are confirmed by 
those of Aroui, et al. (2009), who illustrated a significant reduction in viability, as 
determined by an MTT assay, when MDA-MB-231 cells were treated at a 
concentration of 2.5 µM. Although the concentrations tested by Inao, et al. (2009) 
differed from that which we tested (0-1 µM vs 0-10 µM), they indicated greater 
sensitivity to doxorubicin in BT-549 cells than in MDA-MB-231 cells, as was seen in 
our study (Inao, et al., 2009). 
Based on these results, a concentration of 2.5 µM was selected for doxorubicin 
treatment for the remainder of this study, as this was considered sufficient to illustrate 
either enhanced or reduced chemosensitivity with starvation in any of the cell lines. 
Additionally, this does not exceed the peak plasma concentration of patients receiving 





4.2.2 Doxorubicin, but not starvation, reduces live cell number in MCF-12A, 
BT-549 and MDA-MB-231 cells 
A live cell count was employed to establish the effects of starvation, doxorubicin and 
the combination thereof on the total number of viable cells. Cells undergoing stress 
may respond in a variety of ways which, among others, may include either a reduction 
in their rate of proliferation, or the induction of cell death (Terzi, et al., 2016). Both of 
these mechanisms would result in a lower live cell count, and it was later established 
through viability studies and cell cycle analysis which accounted for the changes in 
cell number.  
In the MCF-12A cell line, both the doxorubicin (p<0.001) and combination treatments 
(p<0.001) significantly reduced the number of live cells when compared to the control 
(Figure 3.16). This is in line with findings from Thomas, et al. (2020) which showed 
that doxorubicin was able to significantly reduce total live cell number in MCF-12A 
cells. Although the model of starvation differed, Thomas, et al. also showed no 
significant reduction in live cell number when MCF-12A cells were subjected to 24 
hours of amino acid deprivation, suggesting that starvation is well-tolerated in these 
cells. However, in our findings, there was no significant difference between the 
doxorubicin and combination groups, which contradicts those of Thomas, et al. This 
may be ascribed to the model of starvation used, as total amino acid deprivation may 
elicit slightly different intracellular processes to our model, which may explain the 
difference in findings. Ultimately, the findings from our study suggest that starvation 
does not increase chemosensitivity in terms of total live cells in this benign cell line. 
In the BT-549 cell line there were significantly fewer live cells in both the doxorubicin 
treatment group (p<0.001) and the combination group (p<0.01) than in the control 
group (Figure 3.16). In the MDA-MB-231 cells, there was also a significant reduction 
in live cell number in the doxorubicin treatment group (p<0.05), as well as the 
combination group (p<0.01) (Figure 3.16). Bar-On, et al., (2007) reported similar 
findings in MDA-MB-231 cells, as well as MCF-7 breast cancer cells. A 72-hour 
incubation period in doxorubicin of differing concentrations (10-100 nM) resulted in 
significant reductions in total cell number. While the concentrations tested were lower 




the principle was illustrated that doxorubicin is able to reduce live cell counts in these 
cells. 
Lastly, while there was a reduction of nearly 20% between the doxorubicin and the 
combination group in the MDA-MB-231 cell line, this did not achieve significance. This 
may, in part, have been due to variations in the data. 
In summary, all three cell lines showed a significant reduction in the total number of 
live cells when treated with doxorubicin, with or without a preceding starvation period. 
However, starvation was not able to significantly reduce the number of live cells when 
administered prior to doxorubicin treatment. 
 
4.2.3 Starvation increases doxorubicin-induced cell death in BT-549, but not 
MCF-12A or MDA-MB-231 cells 
To further examine the effect of starvation on chemosensitivity, cell death was 
assessed through the use of flow cytometry with propidium iodide. Propidium iodide is 
excluded from viable cells due to its inability to permeate intact cell membranes. When 
cells become non-viable, membrane integrity is lost, which allows the dye to enter the 
cell and serve as a marker for cell death. 
In both the MCF-12A and MDA-MB-231 cell lines, there were no significant differences 
in the percentage of dead cells between any of the groups (Figure 3.17). Interestingly, 
Aroui, et al. (2009) also indicated that in the latter, doxorubicin was not able to 
significantly increase the proportion of dead cells at a concentration of 2.5 µM. This 
was established using flow cytometry to determine the fraction of sub-G1 cells and was 
followed by fluorescent microscopy with Hoescht staining as an additional measure of 
cell death. However, these findings are in contrast with a study by Pilco-Ferreto & 
Calaf (2016), wherein it was reported that doxorubicin induces apoptosis in MCF-10A, 
MCF-7 and MDA-MB-231 cells. Treatment with doxorubicin was accompanied by a 
significant increase in the expression of Bax, caspase 3 and caspase 8, and 
decreased Bcl-2. However, the number of non-viable cells was never directly 
assessed. This suggests that the technique used to quantify cell death may affect the 
reported efficacy of doxorubicin to cause apoptotic cell death. For the present study, 




(as opposed to techniques which use proxies or indicators, such as MTT assays and 
western blotting, respectively), reduces the risk for bias as the cell count is performed 
by the flow cytometer, and is generally accepted as an accurate technique. However, 
this technique does not provide insight into apoptotic signalling pathways, should they 
be upregulated in response to treatment. 
In the BT-549 cells, the only group with a significantly higher proportion of dead cells 
than the control was the combination group (p<0.001) (Figure 3.17). Interestingly, 
while doxorubicin treatment alone resulted in approximately 6.5% cell death, a 
starvation period administered prior to doxorubicin treatment significantly increased 
this to approximately 8.9% (p<0.01). The latter, when represented as a percentage of 
original cell death, resulted in 35.5% more cell death than doxorubicin was able to 
induce alone. Ultimately, this finding suggests that a period of starvation prior to 
doxorubicin treatment significantly increased drug sensitivity in these cells. 
Furthermore, if a higher concentration of doxorubicin or a different technique to 
quantify cell death were used (such as western blotting for markers of apoptosis), 
these effects may have been more pronounced. As autophagy is reported to play a 
role in treatment resistance in breast and other types of cancer cells (Park, et al., 2016; 
Jiang, et al., 2017; Jung, et al., 2017; Rupniewska, et al., 2018), we suspect that the 
lack of autophagic upregulation at the 24-hour starvation time point may have 
rendered this specific cell line more susceptible to chemotherapy-induced cytotoxicity. 
At 24-hours, the BT-549 cells did not display an increase in autophagic flux, as 
illustrated by the quantification of Atg5 (Figure 3.4), p62 (Figure 3.5), LC3-II (Figure 
3.6) or autophagic puncta (Figure 3.7).  
In summary, a starvation period of 24 hours prior to treatment was able to significantly 
improve chemosensitivity in the BT-549 cells. Additionally, our findings also indicate 
that doxorubicin acts through various mechanisms to reduce cell viability, which may 
or may not include the induction of apoptosis. This is probably dose-, duration- and 
cell-dependent. Additionally, there may be other mechanisms by which the changes 






4.2.4 Starvation sensitises MCF-12A, BT-549 and MDA-MB-231 cells to 
doxorubicin when using bio-reductive capacity as an indicator of cell 
viability 
A WST1 viability assay was conducted to further examine the effect of starvation on 
chemosensitivity. 
In the MCF-12A, BT-549 and MDA-MB-231 cell lines, there was a significant reduction 
in cell viability following incubation with doxorubicin (p<0.0001; p<0.05; p<0.01, 
respectively) (Figure 3.18). This is in agreement with a study by Pilco-Ferreto & Calaf 
(2016) where an MTT assay was used to illustrate that 2 µM of doxorubicin significantly 
reduced cell viability in MCF-10A, MCF-7 and MDA-MB-231 cells.  
The effect of doxorubicin treatment was significantly enhanced in the MCF-12A, BT-
549 and MDA-MB-231 cells when preceded by a 24-hour starvation period (p<0.01; 
p<0.05; p<0.05, respectively) (Figure 3.18). In a study by Lee, et al. (2012), similar 
findings were reported. After a 24-hour period in starvation-mimicking media, the 
following cell lines all showed increased chemosensitivity to doxorubicin: MCF-7 
breast adenocarcinoma, 4T1 mouse mammary carcinoma, HeLa and A431 cervix 
squamous cell carcinoma, C42B human prostatic carcinoma, GL26 mouse glioma 
cells, ACN neuroblastoma cells and MZ2-MEL malignant skin melanoma. Starvation 
conditions were simulated using low-glucose media and reduced serum (1% as 
opposed to 10%), and viability assessed by MTT assays (Lee, et al., 2012). 
However, as previously elucidated, a WST1 assay is only an indirect indicator of cell 
viability, but a direct indicator of bio-reductive capacity as it relies on reduction by 
NAD(P)H at the mitochondria (Milanese & Mastroberardino, 2020). The changes in 
viability estimated by WST1 assay in Figure 3.18 do not correspond to the changes in 
live cell number seen in Figure 3.16. It may therefore be possible that the effect of 
cellular stress on metabolic activity may influence the reduction of tetrazolium salts 
used in viability assays. This is especially true in the context of doxorubicin: DNA 
damage has been reported to upregulate the production of NAD(P)H, which increases 
cellular bio-reductive capacity (Milanese & Mastroberardino, 2020). This notion is 
supported by Van den Berghe, et al. (2013), who noted that many conditions and 
treatments can enhance or reduce respiratory activity within the cell, compromising 




recommendations are that these viability assays be accompanied by other indicators 
of cell viability or cell death. Ultimately, when supported by a live cell count, or other 
indicators of cell viability, this technique may provide some insight into cellular 
metabolic activity in response to stress (Van den Berghe, et al., 2013). 
 
4.2.5 Starvation reverses doxorubicin-induced G2/M arrest in MCF-12A and 
MDA-MB-231, but not BT-549 cells 
To establish the effect of starvation on chemosensitivity in terms of cell cycle 
progression and growth arrest, cell cycle analysis was performed using the BD 
FACSMelody flow cytometer.  
Compared to the control group in the MCF-12A cell line, the doxorubicin treatment 
group had significantly fewer cells in the G0/G1 phase (p<0.0001), significantly more 
in the S phase (p<0.001), and more cells in the G2/M phase, although this did not 
achieve significance (p=0.07) (Figure 3.19). The former was observed by both Harvey, 
et al. (2019) and Ibiyeye, et al. (2019) in MCF-10A cells in response to doxorubicin 
treatment. However, as previously described, when results are presented as 
percentages of a total, rather than as crude values, a loss in one category may yield 
a natural increase in another. This may explain the increase in the proportion of cells 
in the S phase, as it may not be the result of an active upregulation of cells in this 
phase.  
When compared to the doxorubicin group, the combination group had significantly 
more cells in G0/G1 (p<0.0001) and significantly fewer cells in G2/M (p<0.001), which 
could suggest that starvation may have reversed the effects of doxorubicin on the cell 
cycle of MCF-12A cells. However, the total number of live cells did not recover when 
doxorubicin was preceded by starvation, and there were no significant changes in cell 
death, which suggests that this was not the case. Considering that doxorubicin causes 
G2/M growth arrest (Bar-On, et al., 2007; Martin, et al., 2007; Newell, et al., 2019), it 
might be possible that this specific effect had been ameliorated in the cells that 
received starvation treatment prior to doxorubicin, and that growth arrest occurred at 
an earlier point in the cell cycle. Doxorubicin may induce growth arrest at the G1 
checkpoint (Bar-On, et al., 2007) or even senescence (Hou, et al., 2019), which 




starvation prior to doxorubicin may have shuttled the cells into quiescence (G0). This 
could provide partial protection from doxorubicin-induced cell damage, as this affects 
dividing cells to a greater extent than those in a temporary non-proliferating phase 
(Terzi, et al., 2016). Ultimately, the total live cell count supports the idea that growth 
arrest occurred in both the doxorubicin and combination groups. To determine 
precisely how starvation modulates cell cycle arrest in doxorubicin-treated MCF-12A 
cells, further investigation would be required. Techniques that quantify cell cycle arrest 
and senescence would provide insight into whether the decrease in live cell number 
in the doxorubicin and combination groups are the result of quiescence, G1 or G2/M 
growth arrest, or senescence. 
In the BT-549 cell line, incubation with doxorubicin promoted a decrease in the 
proportion of cells in the G0/G1 phase (p<0.001) and an increase of those in the S 
phase (p<0.0001). There was no significant change in the proportion of cells in the 
G2/M phase. Between the doxorubicin treatment group and the combination group, 
there were also no significant differences in the percentage of cells in the G0/G1 phase 
or the G2/M phase (Figure 3.20). Thus, starvation did not significantly alter the effect 
of doxorubicin on the cell cycle in the BT-549 cells.  
In the MDA-MB-231 cell line, doxorubicin caused a significant reduction in the 
proportion of cells in the G0/G1 phase (p<0.0001), and a significant increase in the 
G2/M phase (p<0.01) (Figure 3.21). Bar-On, et al. (2007) observed this same trend in 
MDA-MB-231 cells treated with doxorubicin, as doxorubicin is known to induce G2/M 
arrest in these cells (Bar-On, et al., 2007; Martin, et al., 2007; Newell, et al., 2019). A 
starvation period prior to doxorubicin treatment significantly increased the proportion 
of cells in the G0/G1 phase (p<0.0001) and decreased those in the G2/M phase 
(p<0.01) (Figure 3.21). Thus, as in the MCF-12A cell line, starvation appeared to 
reverse the effects of doxorubicin on the cell cycle. However, this was also not the 
case in MDA-MB-231 cells, as the total number of live cells was lower in the 
combination group than in the doxorubicin group, although this was not significant. In 
other words, the reversal of doxorubicin’s effect on the cell cycle or growth arrest would 
have been accompanied by an increase in live cell number. As this was not the case 
in the combination group, it may be speculated that starvation altered the point at 




The same possibilities exist in the MDA-MB-231 cell line as in the MCF-12A cell line: 
a starvation period prior to doxorubicin treatment could have shuttled the cells into 
either quiescence (G0), senescence, or G1 growth arrest, as opposed to G2/M growth 
arrest seen in the doxorubicin group. If the MDA-MB-231 cells had entered 
quiescence, this would compromise treatment efficacy, as quiescence would buffer 
them against the DNA damage induced by doxorubicin during DNA synthesis and cell 
division (Terzi, et al., 2016). Senescence, on the other hand, might be a better 
alternative as doxorubicin is reported to also induce senescence in MDA-MB-231 cells 
(Inao, et al., 2019). This would reduce the number of cells able to actively divide, 
thereby reducing tumour volume and growth in vitro (Capparelli, et al, 2012). 
Additionally, senescence may be associated with increased susceptibility to apoptotic 
cell death when the cells are presented with an adjuvant therapy, such as targeted 
antibody therapies (Inao, et al., 2019). However, senescence may also be 
accompanied by the senescence-associated secretory phenotype (SASP), which is 
associated with an increased production of inflammatory cytokines, chemokines and 
growth factors (Milczarek, 2020). This has been reported to contribute to the 
stimulation of non-senescent cancer cells within the population, and promote tumour 
recurrence (Inao, et al., 2019; Milczarek, 2020). 
Ultimately, in improving treatment efficacy, an increase in apoptotic cancer cell death 
is the ultimate goal of any treatment or adjuvant strategy (Inao, et al., 2019). 
Irreversible growth arrest, in the form of senescence, is sometimes viewed as an 
adequate alternative, although this is not without challenges of its own (Terzi, et al., 
2016). Reversible growth arrest and quiescence are not generally accepted as positive 
outcomes, as relapse and recurrence are likely (Terzi, et al., 2016). However, in order 
to thoroughly explore the effect of starvation on doxorubicin-induced growth arrest, 
markers of cell cycle arrest and senescence would need to be quantified. This would 
illustrate whether the decrease in live cell number in the doxorubicin and combination 
groups are the result of quiescence, G1 or G2/M growth arrest, or senescence. 
Lastly, in a study by Newell, et al. (2019), doxorubicin also promoted an increase in 
the proportion of MDA-MB-231 cells in the G2/M phase, indicating cell cycle arrest at 
this point. G2/M arrest is often induced in response to DNA damage. This arrest either 
facilitates the repair of DNA or promotes apoptosis, with the latter being the goal of 




with DHA prior to doxorubicin treatment increased the proportion of cells in G2/M 
growth arrest. Interestingly, this pre-treatment also decreased cell viability (WST1), 
upregulated the expression of pro-apoptotic proteins (caspase 10), and apoptotic cell 
death when compared to the group that received doxorubicin alone (Newell, et al., 
2019). This may suggest that the increase in cells within the G2/M growth arrest phase 
is an indication of improved drug efficacy and may be accompanied by increased cell 
death. In this case, our findings may indeed suggest that a period of starvation did not 
enhance chemosensitivity in these cells but may have compromised treatment 
efficacy. This may be supported by studies which find that upregulated autophagic 
processes contribute to treatment resistance in breast and other types of cancer cells 
(Park, et al., 2016; Jiang, et al., 2017; Jung, et al., 2017; Rupniewska, et al., 2018). In 
the findings from part one of the present study, it was observed that the MDA-MB-231 
cells had significantly higher autophagic flux at the 24-hour starvation time point. This 
was determined by western blotting for Atg5 (Figure 3.4), p62 (Figure 3.5) and LC3-II 
(Figure 3.6). This theory is supported by findings from Thomas, et al. (2020) who 
discovered that the inhibition of autophagy through both Atg5 siRNA and bafilomycin 
treatment significantly increased caspase3/7 expression in MDA-MB-231 when 
treated with doxorubicin. However, in order to confirm this in our model of starvation, 
more extensive investigation into the effects of autophagy on chemoresistance would 
be required.  
In summary, all three cell lines showed significant decreases in the proportion of cells 
in the G0/G1 phase when treated with doxorubicin. However, in both the MCF-12A and 
MDA-MB-231 cell lines, this trend was reversed in the combination group, along with 
significant reductions in the proportion of cells in G2/M when compared to the 
doxorubicin group. However, based on the total live cell counts, it may be suggested 
growth arrest still occurred in the combination groups of these two cell lines. Since 
inferences on senescence cannot be made from cell cycle analyses, we recommend 
future studies examine markers of growth arrest and senescence to determine 







Chapter 5: Summary and Conclusion 
 
The aims of this study were to investigate the intracellular response of a benign breast 
epithelial and two breast cancer cell lines to starvation, and to determine how this 
influences chemosensitivity. We hypothesised that a period of starvation prior to 
doxorubicin treatment would selectively enhance treatment efficacy in cancer cells, 
while offering protection to non-malignant cells. Investigations into the intracellular 
response to starvation demonstrated that the MCF-12A benign cell line downregulated 
growth and proliferation pathways during starvation, while the MDA-MB-231 cell line 
showed upregulation instead. The BT-549 cell line showed no significant changes in 
growth and proliferation signalling during starvation. While the MCF-12A and MDA-
MB-231 cell lines had significantly upregulated autophagic activity at 24 hours of 
starvation, the BT-549 cell line showed no change in autophagic flux at this time point. 
This may have rendered this cell line vulnerable to doxorubicin-induced cytotoxicity, 
as the other two cell lines showed no significant increase in cell death when 
doxorubicin treatment was preceded by a starvation period. In addition, starvation prior 
to treatment ameliorated doxorubicin-induced G2/M growth arrest in the MCF-12A and 
MDA-MB-231 cell lines, although further investigation is required to establish the exact 
effect of starvation and doxorubicin on cell cycle arrest. In conclusion, our results 
illustrated that the BT-549 breast cancer cell line was indeed sensitised to doxorubicin 
when starved for 24 hours prior to administration. However, this did not hold true for 
the MDA-MB-231 breast cancer cell line. The MCF-12A cells did not display enhanced 







Chapter 6: Limitations and Future Recommendations 
 
With regards to variability and statistical significance, we recommend an increase in 
the number of replicates performed for western blotting analyses, as this semi-
quantitative technique displays a natural variability. Additionally, there is room for 
better optimisation of the protocols for each protein. This may also help to reduce 
variation and improve accuracy of the data obtained from this technique. 
To strengthen the insight into metabolic signalling pathways, we recommend that 
mTOR, AMPK and phosphorylated PI3K be included in future studies. It should be 
noted that although the total level of PI3K provides insight into intracellular expression, 
it does not depict activation. In order to fully appreciate the relative amount of active 
PI3K, phosphorylated PI3K should be quantified as well. However, we were unable to 
optimise this protocol within the given time constraints as the antibody showed severe 
non-specific binding, and specific bands were undetectable. We recommended that 
this protocol be optimised for future studies to include phosphorylated PI3K in the 
outcomes. 
We also recommend that a greater number of cells be imaged during 
immunocytochemistry. The cells utilised rejected the plasmid quite rapidly, and as 
such, imaging cells with a strong eGFP signal proved troublesome. For future studies, 
it may be worthwhile investigating the use of fluorescent antibodies for this purpose. 
For future studies, it may also be worth investigating whether starvation and 
doxorubicin treatment result in a permanent exit from the cell cycle by quantifying 
markers of senescence (p21, RB and p53). Additionally, we recommend that apoptotic 
signalling pathways be explored by doing western blot analyses for markers of 
apoptosis. 
This study used an in vitro model, and any conclusions should be limited as such, not 
extrapolated to in vivo or ex vivo conditions. As a whole, starvation is a difficult 
metabolic state to accurately replicate under in vitro conditions. An in vivo model 
should be considered for future studies, due to the inclusion of systemic factors 
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Appendix A: Reagents 
 
Phosphate buffered saline (PBS): 
• 16g NaCl 
• 0.4g KCl 
• 2.882g Na2HPO4 
• 0.481g KH2PO4 
 
1. Dissolve reagents in 1.8L dH2O. 
2. Adjust pH to 7.4 and fill up to 2L with dH2O. 
3. Store at room temperature. 
 
Modified RIPA buffer: 
• 790mg Tris-base 
• 900mg NaCl 
• 10ml 10% NP-40 
• 10ml 10% Na-deoxycholate 
• 5ml 100mM EDTA 
• 5ml 100mM EGTA 
• 1ml 10% SDS 
 
1. Add Tris-base and NaCl to 50ml dH2O and stir until dissolved. 
2. Adjust pH to 7.4. 
3. Add NP-40 and Na-deoxycholate and stir until dissolved. 
4. Add EDTA, EGTA and SDS and stir until dissolved. 
5. Adjust to final volume of 100ml with dH2O. 




Appendix B: Protocols 
 
Protocol 1: Western blotting 
Cell harvesting using the cell scraper 
1. Prepare reagents by placing PBS, RIPA Stock Buffer and eppies on ice. 
2. Prepare RIPA Buffer by adding the following reagents per 1 ml of RIPA: 
o 42 μL Protease Inhibitors Cocktail 
o 5 μL PMSF (Add just before use, half-life of 30min) 
o 5 μL Na3VO4 
o 5 μL NaF 
3. Retrieve cells. 
4. Remove media from cells with Pasteur pipette. 
5. Wash twice with ice-cold PBS using a Pasteur pipette 
6. Add 80 μL RIPA Buffer per well in 6-well plate or 150 μL per T25 flask. 
7. Incubate on ice for 2-5 minutes. 
8. Using a cell scraper, scrape the cells loose and collect in corner of flask. 
Remember to clean the scraper with ethanol between different groups. 
9. Collect the suspension from the flask/plate and transfer to a pre-cooled eppie. 
10.  Sonicate this for 5 seconds @ 5 amplitude. 
11. Incubate in the fridge, on ice, until the foam has settled. (Alternatively, eppies 
can also be stored at this point in the -80°C freezer). 
12. Centrifuge for 2 minutes @16.3g and 4°C. 
13. Collect the supernatant in new pre-cooled eppie. 
14. Store eppies at -80°C, or perform a Bradford assay to determine the volume 
needed for 50 μg of protein. 




1. If samples are frozen, thaw the protein samples on ice. 




3. Prepare a BSA working solution (200 μg/ml) by diluting 100 μl BSA with 400 μl 
dH2O (50 μL BSA + 450 μL dH20 if using 2 mg/ml BSA stock). Vortex to mix. 
 
4. Prepare Bradford standards as follow (in duplicate): 
Volumes of components used to establish Bradford standards. 
μg Protein 200 μg/ml BSA dH2O Bradford Reagent 
0 (Blank) 0 μl 100 μl 900 μl 
2 10 μl 90 μl 900 μl 
4 20 μl 80 μl 900 μl 
8 40 μl 60 μl 900 μl 
12 60 μl 40 μl 900 μl 
16 80 μl 20 μl 900 μl 
20 100 μl 0 μl 900 μl 
 
5. Vortex the protein samples. 
6. For each Bradford sample, add 5 μl of protein sample to 95 μl dH20 and 900 μl 
Bradford reagent. Prepare each sample in duplicate. 
7. Vortex the Bradford samples and standards. 
8. Zero the spectrophotometer with a blank and set the absorbance @ 595 nm. 
9. Read the absorbencies of each sample. 
10. Draw a standard curve using an Excel graph and plot the values of the sample 
to determine the concentration of protein in each sample. 
 
Stain-free SDS-Page Fast Cast Gel Protocol 
Using Bio-Rad® TGX Stain-Free™ FastCast™ Acrylamide Kit, 12%. 
1. Get clean pairs of spacer plates and short plates, BioRad casting frames 
(green), casting stands and the rubber gaskets that go in the bottom of the 
stand. 
2. Place gaskets in the grooves at the base of the casting stands. 
3. Clean the plates thoroughly with ethanol and place them in the casting frames 




4. Get 3 small beakers and label them for H2O, resolving gel (bottom) and stacking 
gel (top). 
5. Make up the required resolving gel according to the recipe given by Bio-Rad® 
to make 4 gels. 
 
Volumes of components used for self-cast resolving gel. 
Resolving Gel 
Gel constituent 4% Gel 
Resolver A 12 mL 
Resolver B 12 mL 
TEMED 12 µL 
10% APS 120 µL 
 
1. Add all the constituents to the beaker, swirling gently to mix. 
2. Using a Pasteur pipette, quickly pour the gel mixture between the two plates up 
to the green line seen at back of the plate from the gasket. Avoid air bubbles by 
pouring in from the one corner. 
3. Allow gel to set (30 to 60 minutes). Prepare 1:10 dilutions of running buffer, 
TBS-T and transfer buffer. 
4. Prepare the stacking gel according to the recipe given by Bio-Rad® to make 4 
gels. 
Volumes of components used for self-cast stacking gel. 
Stacking Gel 
Gel constituent 4% Gel 
Stacker A 4 mL 
Stacker B 4 mL 
TEMED 8 µL 
10% APS 40 µL 
 
1. Add all the constituents with gentle swirling to mix 
2. Using a plastic Pasteur pipette, quickly pour the gel mixture between the two 




3. Insert the appropriate comb gently, pushing down and avoiding bubble 
formation. 
4. Allow to set for 1 hour. 
5. Retrieve the standard protein marker from the freezer and allow to equilibrate 
to room temperature. 
 
Western Blot Running Protocol 
Day 1 
1. Prepare BioRad Fast Cast Stain-Free gels or Self Cast according to 
instructions. 
2. Thaw protein samples on ice, which are prepared in a 2:1 ratio of protein sample 
to Laemli’s buffer. 
3. Punch a hole in the lid of each eppie, mix by vortexing briefly and boil for 5 
minutes at 95°C. 
4. Spin samples down with quick pulse. 
5. Assemble the gasket 
• Assemble the gels onto the gasket with the comb facing inside 
• Fill the gasket with running buffer. Check for leaks. 
• Carefully remove the combs and rinse out wells with P200 pipet (set to 
approx. 100 μL) and a yellow tip. 
6. Load the ladder (4 μL BLUeye). 
7. Load the samples. 
8. Place the gasket into the tank and fill with running buffer. Re-fill gasket if 
necessary. 
9. Attach the lid and plug into power pack. 
10. Run at 100 V for approximately 10 minutes (until sample has entered gel). 
11. Increase to 150 V and run until blue dye front reaches the bottom of the gel 
(approximately 1 hour). 
12. When finished, activate immediately  
• Activate stain-free properties of gel on ChemiDoc (gel activation 





Western Blot Transfer Protocol 
Day 1 
1. Prepare for transfer: 
a. Soak two pieces of blotting paper in transfer buffer for 2 minutes. 
b. Activate a piece of PVDF membrane in 100% methanol for 10-15 
seconds and then soak in transfer buffer for 2 minutes. 
c. Size 7 cm x 8.4 cm – blotting paper and membrane should be same size, 
preferably gel also 
2. Assemble the transfer sandwich on the cassette base (anode) by placing one 
piece of wet extra thick or 3 pieces of thick filter paper on the bottom, then the 
membrane, the gel, and finally, the remainder of the wet filter paper on top. Use 
the blot roller to remove air from between the assembled layers. 
3. Once the stacks are positioned in the cassette base, place the cassette lid on 
the base. The lid is reversible, but ensure that the electrical contacts fit closely 
into the slots in the base. Press the lid down firmly and turn the dial clockwise 
to engage the lid pins into the locking slots.  
4. Load a second cassette if desired. 
5. Slide the cassette (with the dial facing up) into the bay until it makes contact 
with the magnetic interlock and you hear a click. Cassettes can be inserted into 
the bays in any order, with or without power to the system.  
6. Select the LIST button from the Home menu and the STANDARD SD transfer 
protocol from the Bio-Rad pre-programmed protocols or the user-defined 
protocol of choice.  
7. To initiate the run, press the navigation button that corresponds to A:RUN for 
the cassette in the upper bay or B:RUN for the cassette in the lower bay.  
8. After transfer, disassemble the stack. 
• Blotting paper can be re-used. 
• Gel can be visualised to determine transfer efficiency if desired. 
9. Label membrane and rinse in 100% methanol. 
• Labelling – only use soft pencil and not markers or pens. 




10. Air-dry membrane  
• Becomes white 
• Hold in fumehood for quicker drying 
11. Re-hydrate membrane in 100% methanol 
• Until translucent, 10-15 seconds 
 
Western Blot Antibody Protocol 
Day 1 
1. Wash membrane in TBS-T for 5 minutes. 
2. Image transfer on membrane on Chemidoc 
• Stain-free blot setting 
• If using for normalisation, make sure image is clean and not over-
exposed. 
3. Block membrane in 5% milk (prepared in TBS-T) for 1 hour with gentle shaking 
• Or 5% BSA (prepared in TBS-T) for when probing for phosphorylated 
proteins. 
4. Wash membrane 3 x for 5 minutes in TBS-T. 
5. Incubate membrane on primary antibody overnight at 4°C. 
a. Prepared in 50 ml centrifuge tube. 
b. Dilute antibody in TBS-T to desired concentration, normally 1:1000. 
c. Attach to rotators in walk-in fridge. 
• Make sure tube/s are straight and rotor is balanced. 
 
Day 2 
6. Retrieve membranes 
• Stored primary antibody in fridge/freezer 
7. Wash membrane 3 x 5 minutes in TBS-T. 
8. Incubate membrane on secondary antibody for 1 hour at room temperature. 
a. Prepared in 50 ml centrifuge tube. 
b. Dilute antibody in TBS-T to desired concentration, normally 1:10 000. 




9. Wash membrane 3 x 5 minutes in TBS-T. 
10. Develop: 
a. Prepare minimum amount of ECL needed in eppie in a 1:1 ratio. 
b. Place membrane on Chemidoc and check position. 
c. Add ECL to the desired area and roll to ensure even spread. Roll away 
excess ECL. 






Protocol 2: Immunocytochemistry 
GFP-LC3 transfection: 
1. Seed a T25 flask and culture until a confluence of 60-70% is attained. 
2. Set aside two 500 µl eppies. 
3. In the first, add 200 µl media, 15 µl P3000 and 3 µl GFP-LC3 plasmid. 
4. In the second, add 200 µl media and 11,25 µl Lipofectamine. 
5. Add the contents of the first eppie to the second, pipetting up and down to mix 
the reagents thoroughly. Incubate for 15 minutes at room temperature. 
6. Remove the media from the T25 flask and add 3 ml of fresh media. 
7. Add the transfection reagents to the T25 flask, and, once closed, move the flask 
in a figure-eight motion to ensure even distribution of reagents. 
8. Incubate for 24-48 hours at 37°C, and refresh with complete media when 
transfection is complete. 
 
Selection of GFP-LC3 cells: 
1. Seed a T25 flask with cells transfected with GFP-LC3. Culture until 
approximately 60-70% confluent. 
2. Aliquot 4 ml of PenStrep-free media into a 15 ml Falcon tube and add 40 µl of 
G418 (50 mg/ml). This yields a final concentration of 0,5 mg/ml. 
3. Remove the media from the T25 and replace with PenStrep-free media 
containing G418. 
4. Incubate for 24-48 hours at 37°C, and refresh with complete media after 
selection is complete. 
 
The addition of LysoTracker Red: 
For an 8-well chamber slide (volume of 200 µl/well): 
1. Add 1 µl of LysoTracker Red (1 mM) to 100µl of media and vortex to get a 
working solution of 10 µM. 
2. Add 2,5 µl of working solution to each well with a total volume of 200 µl. 




Protocol 3: Cell cycle analysis 
1. Seed and culture cells in either 6-well plates or T25 flasks so that a minimum 
of one million cells will be attained at the end of the treatment period. 
2. Label each treatment group and treat accordingly until cells are ready to be 
harvested. 
3. Remove media and wash all treatment groups once with warm PBS. 
4. Trypsinise cells and transfer the cells from each group to separate labelled 
tubes. Pool triplicate wells (if using a 6-well plate) from each treatment group 
to form one sample per group.  
5. Rinse wells with PBS and add to corresponding tubes so that any remaining 
cells may be collected and pooled with their respective groups. 
6. Take a 20 µl sample from each group and count using a haemocytometer to 
obtain the total number of cells per group. 
7. Centrifuge tubes at 1750 rpm for 4 minutes. 
8. Resuspend in PBS and centrifuge again at 1750 rpm for 4 minutes. 
9. Fix cells by resuspending the pellet in ice-cold 70% ethanol while vortexing to 
avoid clump formation. 
10. Incubate cells in ethanol on ice for 1 hour. 
11. Centrifuge at 3000 rpm for 5 minutes. 
12. Carefully wash twice with PBS, avoiding cell loss. 
13. Resuspend each pellet in 50 μl RNase A (100 µg/ml) and 400 μl PI (50 µg/ml). 
14. Wrap tubes in foil to protect from direct light, and incubate at room 
temperature for 30 minutes. 





Protocol 4: Cell viability assay using WST1 
1. Seed and culture cells in a 48-well plate.  
2. Label each group and treat accordingly. 
3. When cells are ready to be analysed, add 10 µl of WST1 reagent to each well 
containing 200 µl of media each. (Do not remove media before adding WST1). 
4. Cover the full plate with foil to protect from light and incubate for 60-120 minutes 
at 37°C. 
5. Uncover the plate, remove the lid, and measure the absorbance at 450 nm on 
Microtiter Plate Reader. 
6. Analyse values by obtaining the mean for each treatment group, and express 





Protocol 5: Live cell count with trypan blue 
 
1. Seed and culture cells in either 6-well plates or T25 flasks. 
2. Label each treatment group and treat accordingly until cells are ready to be 
harvested. 
3. Pre-label a 15 ml tube for each experimental group. 
4. Remove media and wash all treatment groups once with warm PBS. 
5. Trypsinise cells and transfer the cells from each group to its respective 
labelled tube. Pool triplicate wells (if using a 6-well plate) from each treatment 
group to form one sample per group.  
6. Rinse wells with PBS and add to the corresponding tubes so that any 
remaining cells may be collected and pooled with their respective groups. 
7. Centrifuge tubes at 1750 rpm for 4 minutes. 
8. Remove supernatant, resuspend in 3 ml PBS and centrifuge again at 1750 
rpm for 4 minutes. 
9. While centrifugation commences, prepare a 500 µl solution of 0.1% trypan 
blue from 125 µl trypan blue 0.4% and 375 µl PBS. 
10. Remove supernatant and resuspend each pellet in 1000 µl of warm PBS. 
11. Transfer 100 µl of this cell suspension to a pre-labelled Eppendorf tube, and 
add 100 µl of 0.1% trypan blue solution, mixing as you resuspend. 
12.  Load 10 µl of this suspension onto each of three grids on Neubauer counting 
chambers.  






Protocol 6: Flow cytometry with propidium iodide staining 
1. Seed and culture cells in either 6-well plates or T25 flasks so that a minimum 
of one million cells will be attained at the end of the treatment period. 
2. Label each treatment group and treat accordingly until cells are ready to be 
harvested. 
3. Remove media and wash all treatment groups once with warm PBS. 
4. Trypsinise cells and transfer the cells from each group to a separate labelled 
tube. Pool triplicate wells (if using a 6-well plate) from each treatment group to 
form one sample per group.  
5. Rinse wells with PBS and add to corresponding tubes so that any remaining 
cells may be collected and pooled with their respective groups. 
6. Take a 20 µl sample from each group and count using a haemocytometer to 
obtain the total number of cells per group. 
7. Centrifuge tubes at 1750 rpm for 4 minutes. 
8. Remove supernatant, resuspend in PBS and centrifuge again at 1750 rpm for 
4 minutes. 
9. Resuspend each pellet in the appropriate volume of PBS to yield a final 
concentration of 106 cells per ml. 
10. Add 400 μl PI (50 µg/ml). 
11. Wrap tubes in foil to protect from direct light. Remove from foil only to analyse 
samples using a BD FACS Melody cell sorter. 
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